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resumo 
 
 
A doença de Alzheimer (DA) é o tipo de demência mais comum. 
Histopatologicamente é caracterizada pela presença de tranças neurofibrilares 
intracelulares (TNF) e de placas senis extracelulares (PS), as quais estão 
rodeadas pela microglia e por astrócitos. A neuroinflamação tem sido 
associada com várias doenças neurodegenerativas. Na DA o processo 
inflamatório, desencadeado pelo aumento da produção e agregação do péptido 
Aβ, desempenha um papel fundamental na patogénese da doença. Nas fases 
inicias, a inflamação possui um papel benéfico na patologia, uma vez que tem 
sido proposto que a microglia e os astrócitos quando ativados estão envolvidos 
na remoção de β-amilóide (Aβ). No entanto, a ativação crónica da microglia 
conduz à produção excessiva de componentes inflamatórios, incluindo 
citocinas. Isto provoca alterações na expressão e processamento da proteína 
percursora de amilóide (PPA), estimulando o aumento da produção e 
acumulação de Aβ, fosforilação anormal da proteína Tau e, 
consequentemente, efeitos neurotóxicos e perda de neurónios. Uma vez que a 
neuroinflamação crónica é uma característica da DA, proteínas inflamatórias 
poderão constituir potenciais candidatos a biomarcadores que auxiliem no 
diagnóstico clínico desta doença. Desta forma, o principal objectivo deste 
trabalho foi identificar biomarcadores inflamatórios para a DA através da 
técnica de citometria de fluxo. Para tal, foram analisadas amostras de plasma 
de doentes que foram, previamente, examinados por testes de avaliação 
cognitiva, clinical dementia rating (CDR) e mini mental (MM). Os sujeitos foram 
divididos em três grupos distintos, o grupo controlo (CDR-/MM-) e dois grupos 
de pacientes, CDR+/MM- e CDR+/MM+. O primeiro grupo de pacientes pode 
conter indivíduos com ligeiras alterações cognitivas (MCI) e o segundo inclui 5 
pacientes clinicamente diagnosticados para DA. A análise dos dados revelou 
diferenças nos níveis de proteínas inflamatórias de ambos os grupos de 
doentes (CDR+/MM- e CDR+/MM+) em comparação com os indivíduos 
saudáveis (CDR-/MM-). Os níveis plasmáticos de interleucina-8 (IL-8) foram 
estatisticamente deferentes (p<0,05) do grupo controlo. Correlação significativa 
entre as concentrações de IL-8 e os estados de CDR foi identificada. 
Adicionalmente, foram observadas correlações entre MCP-1 e IL-8 e a IL-6. 
Em conjunto, estes resultados sugerem que a IL-8 poderá ser um potencial 
biomarcador não só para a DA mas também para o diagnóstico precoce de 
demência. 
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abstract 
 
Alzheimer’s disease (AD) is the most common form of dementia. 
Histopathologically it is characterized by the presence of two major hallmarks, 
the intracellular neurofibrillary tangles (NFT) and the extracellular senile 
plaques (SP), which are surrounded by activated astrocytes and microglia. 
Neuroinflammation has been associated with some neurodegenerative 
diseases. In AD the inflammatory process, prompted by increased Aβ 
production and aggregation, was reported to have a fundamental role in 
disease pathogenesis. In early stages the inflammation could have a beneficial 
role in the pathology, since it has been proposed that the microglia and 
astrocytes activated could be involved in (amyloid β) Aβ clearance. 
Nevertheless, the chronic activation of the microglia leads to excessive 
production of the inflammatory components, including cytokines. It promotes 
alterations in amyloid precursor protein (APP) expression and processing, 
stimulating the increase of Aβ accumulation, abnormal Tau phosphorylation 
and, consequently, neurotoxic effects, irreversible damage and loss of neurons.  
Since chronic neuroinflammation is a feature of AD, inflammatory proteins may 
constitute potential biomarkers candidates to assist clinical diagnosis of this 
dementia. Thus, the main aim of this study was to identify putative inflammatory 
biomarkers for AD by flow citometry analysis. For plasma samples of 
individuals examined by clinical dementia rating (CDR) and mini mental (MM) 
diagnostic tests were used. Subjects were subdivided in 3 distinct groups, a 
control group (CDR-/MM-) and two patient groups, CDR+/MM- and 
CRD+/MM+, the former may include mild cognitive impairment (MCI) patients 
and the latest group included 5 patients clinical diagnosed as AD. Data analysis 
revealed differences in the inflammatory proteins levels of both patients groups 
(CDR+/MM- and CDR+/MM+) in comparison to healthy individuals (CDR-/MM-
). Interleukin-8 (IL-8) plasma levels were statistically different (P<0,05) from 
control group. Significant correlation between IL-8 concentrations and the CDR 
stages was also identified. Additionally, correlations of monocyte 
chemoattractant protein-1 (MCP-1) with both IL-8 and IL-6 were observed. 
Taken together these findings suggested that IL-8 could be a potential 
biomarker not only for AD but also for diagnosis of initial stages of dementia. 
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AD  Alzheimer Disease 
AICD  APP Intracellular Domain 
ApoE  Apolipoprotein E 
APP  Amyloid Precursor Protein 
Aβ  Amyloid β peptide 
BACE  Beta-site APP Cleaving Enzyme 
BBB  Blood Brain Barrier 
BCA  Bicinchonic Acid 
BCSFB  Blood-Cerebrospinal Fluid Barrier 
BDNF  Brain-Derived Neurotrophic Factor 
BSA  Bovine Serum Albumin 
CBA  Cytometric Bead Array 
CCR  CC Receptors 
CD  Cluster of Differentiation 
CdK  Cyclin-dependent Kinase 
CDR  Clinical Dementia Rating 
CI  Confidence Interval 
COX  Cyclooxygenase 
CNS  Central Nervous System 
CSF  Cerebrospinal Fluid 
CT  Computerized Tomography 
CXCR  CXC Receptors 
C1 – C9 Complement Factors 
DAMP  Damage-Associated Molecular Patterns 
DLB  Dementia with Lewy Bodies 
ECL  Enhanced Chemiluminescence 
EDTA  Ethylenediamine Tetraacetic Acid 
EOAD  Early-Onset AD  
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ERL  Glutamate-Leucine-Arginine Motif 
ERK  Extracellular Signal-Regulated Kinase 
FAD  Familial Alzheimer’s Disease 
FBS  Fetal Bovine Serum 
FTD  Frontotemporal Dementia 
GDNF  Glial-Derived Neutrophic Factor 
GDS  Geriatric Depression Scale 
GSK  Glycogen Synthase Kinase 
H0  Null Hypothesis 
HD  Huntington Disease 
ICAM-1 Intercellular Adhesion Molecule 1 
IL  Interleukin 
INF  Interferon 
iNOS  inducible Nitric Oxide 
LOAD  Late-Onset AD 
MAPK  Mitogen-Activated Protein Kinase 
MCI  Mild Cognitive Impairment 
MCSF  Macrophage Colony-Stimulating Factor 
MCP-1  Monocyte Chemoattractant Protein 1 
MEM  Minimal Essential Medium 
MHC  Major Histocompatibility Complex 
MIP  Macrophage Inflammatory Protein 
MM  Mini Mental 
MRI  Magnetic Resonance Imaging 
NFkB  Nuclear Factor-kappa B 
NFT  Neurofibrillary Tangles 
NO  Nitric Oxide  
NOD  Nucleotide-Oligomerization Binding Domain 
NSAID  Non Steroids Anti-Inflammatory Drugs 
PAMP  Pathogen-Associated Molecular Patterns 
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PBS  Phosphatase Buffer Salt 
PET   Positron Emission Tomography 
PHF  Paired Helical Filaments 
PGE2  Prostaglandin E2 
PRR  Pattern Recognition Receptors 
PSEN1  Presenilin 1 
PSEN2  Presenilin 2 
P-Tau  Phospho-Tau 
PE  Phycoerythrin 
RAGE  Receptors for Advanced Glycosylation End Products 
RANTES Regulated on Activation, Normal T cell Expressed and Secreted 
RXR  Retinoid X Receptors 
ROS  Reactive Oxygen Species 
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
SP  Senile Plaques 
SPECT  Single Photon Emission Computerized Tomography 
TLR  Toll-Like Receptors 
TGF  Transforming Growth Factor 
TNF  Tumor Necrosis Factor 
T-Tau  Total-Tau 
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1.1. Concept of inflammation 
Our body is constantly exposed to several exogenous and endogenous agents, 
which can disturb its normal function and, consequently be harmful for us. The organism 
has various defense mechanisms to fight and remove or eliminate these injurious 
components, in order to maintain the homeostasis and ensure function of all organs and 
tissues. 
The inflammatory process is a defense mechanism extremely important under 
pathological conditions, consisting in a physiological immune response that occurs in 
vascularized tissues (Ratner et al. 1996), against a lesion or damage caused by physical 
agents, chemicals or microorganisms. Several inflammatory cells are involved in this 
process, such as lymphocytes, neutrophils, macrophages, among others. After damage, 
many signaling cascades are activated to prevent severe consequences. Acute 
inflammation is the first process and can progress to chronic inflammation if the 
inflammatory stimulus persists for a long period, previously impacting on health (Almeida 
et al. 2012; Schmidt-bleek et al. 2014). 
 
1.1.1. Acute inflammation 
Acute inflammation consists in a quick response (from minutes to days) to a 
foreign agent and is responsible to trigger defense mediators of the organism to the 
injury site. Acute inflammation can be divided in two phases: vascular and cellular. The 
acute vascular response results from vasodilation and increased capillary permeability 
due to vascular endothelium alterations. Consequently, blood flow increases causing 
redness, exudation of fluid and plasmatic proteins (edema) and migration of leukocytes 
(predominantly neutrophils) into the damaged tissues, named of Exudation Process 
(Kumar et al. 2009).  
When injury is severe to the tissues, or if infection occurs, the acute cellular 
response takes place over the next few hours. This phase is characterized by a sequence 
of events that begin with the appearance of monocytes and with an increasing amount of 
neutrophils into extravascular tissue (Brown and Badylak 2013). Due to the presence of 
adhesion molecules, such as selectins, immunoglobulins, integrins and glycoproteins, on 
the surface of the neutrophils and in the endothelial surfaces (Ratner et al. 1996; Kumar 
et al. 2009),  attachment of these cells within the blood vessels occurs, followed by cell 
crossing through the endothelium. The first event is a process called margination, and the 
second called diapedesis. Then, the leukocytes migrate to the injured site along a 
chemotactic gradient, which is generated by chemokines (Section 1.3.1.2.) in order to 
ensure that leukocytes are recruited to the tissues where the stimuli is present. This 
process is defined as chemotaxis and occurs by binding of granulocytes, monocytes and 
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lymphocytes (minor percentage) to the leukocytes surface receptors in response to 
chemotatics stimulus (Kumar et al. 2009).  
Activated neutrophils and macrophages can lead to death of the injurious 
microorganism by two different processes, phagocytosis and enzymes release. 
Phagocytosis is a three-step process in which the injurious agent undergoes recognition 
and neutrophil attachment, engulfment, and killing or degradation (Ratner et al. 1996; 
Kumar et al. 2009). Nonetheless, during chemotaxis and phagocytosis, activated 
leukocytes can release toxic metabolites and proteases which can be responsible for the 
tissue lesion (Kumar et al. 2009). Figure 1 shows the multistep process of leukocyte 
migration through blood vessels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Migration process of leukocytes through the blood vessels. First, leukocytes (neutrophils) 
undergo roll, becoming activated and adhering to the endothelium. Then transmigrate across the 
endothelium, pierce the basement membrane, and migrate toward chemoattractants emanating from the 
source of injury. Different molecules play an important role in different steps of this process: selectins are 
involved in roll; chemokines are related to neutrophils activation to increase integrins avidity; integrins are 
associated to firm adhesion; and CD31 (PECAM-1) in transmigration. Neutrophils express low levels of L-
selectin and they bind to the endothelial cells through P- and E-selectins. ICAM-1, intercellular adhesion 
molecule 1; TNF, tumor necrosis factor (taken from Kumar et al. 2009).  
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Acute inflammation can be triggered by infections (bacterial, viral, fungal, 
parasitic) and microbial toxins; by tissues necrosis from any cause such as ischemia, 
trauma and physical and chemical agents (irradiation, environmental substances); foreign 
bodies, for example spliters, dirt and sutures; immunological reactions or hypersensitivity 
reactions (Kumar et al. 2009).  
 
 
1.1.2. Chronic inflammation 
Chronic inflammation has a prolonged duration (from weeks to months) and may 
follow acute inflammation when the damage is sufficiently severe and/or if there is a 
prolonged exposure to the initial inflammatory stimuli (Figure 2) (Ratner et al. 1996; 
Kumar et al. 2009). It can be initiated by persistent infections by microorganisms, such as 
mycobacteria, some viruses, fungi and parasites; immune-mediated inflammatory 
diseases (autoimmune diseases); and prolonged exposure to potentially toxic agents, 
which can be either exogenous or endogenous. Alternatively, it may begin insidiously 
without any manifestations of an acute reaction (Figure 2), causing tissue damage in 
some of the most common human diseases, including rheumatoid arthritis, 
atherosclerosis, pulmonary fibrosis and, more recently, it has also been related to 
Alzheimer disease (AD) (Kumar et al. 2009).  
Chronic inflammation is characterized by the presence and infiltration of 
mononuclear cells such as macrophages (Brown and Badylak 2013), lymphocytes and 
plasma cells (Ratner et al. 1996); tissue destruction induced mainly by inflammatory cells; 
and, ultimately, reparation of the damaged tissue. The latter step involves connective 
tissue replacement with proliferation of small blood vessels, a process called 
angiogenesis, and fibrosis of the tissue (Kumar et al. 2009). Macrophages are responsible 
to produce and secrete a lot of biologically active products, including pro- and anti-
inflammatory cytokines (Brown and Badylak 2013), complement components, 
chemotactic factors, neutral proteases, arachidonic acid metabolites, reactive oxygen 
species, coagulation factors and growth-promoting factors (Ratner et al. 1996). In 
addition, macrophages are involved in microbial killing, cleaning up cellular and tissue 
debris, and they also seem to be very important in tissues remodeling. For all of these 
reasons, macrophages are considered the most important cells in chronic inflammation. 
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In summary, the main features of the inflammatory response include: 
vasodilation, i.e. widening of the blood vessels in order to increase the blood flow to the 
infected area; increased vascular permeability, which allows diffusible components to 
enter the site; cellular infiltration by chemotaxis, or the directed movement of 
inflammatory cells through the walls of blood vessels into the injury site; changes in 
biosynthetic, metabolic, and catabolic profiles of many organs; and activation of the 
immune system cells as well as of complex enzymatic systems of blood plasma. Of course, 
the degree to which these events occur is usually proportional to the severity and the 
extent of the injury, and inflammation ends when the inflammatory stimulus is eliminated 
and removed, otherwise the phase of chronic inflammation. 
 
 
 
 
Figure 2 – Chronic inflammation causes: acute inflammation or injury. If acute inflammation 
persists it can progress to a chronic inflammatory process. The components involved in each 
reaction are described in the scheme (adapted from Kumar et al. 2009). 
  
Inflammatory Biomarkers in Alzheimer’s Disease                                                                     Cátia Barra 
 
5 
 
 
1.1.3. Inflammatory mediators 
Inflammatory mediators can derive either from cells or from plasma proteins 
(Table 1). The cell-derived mediators are sequestrated inside of intracellular granules (e.g. 
histamine in mast cell granule), which are rapidly secreted by exocytosis or synthetized de 
novo in response to a stimulus. The main cells that produce or secrete this type of 
mediators are platelets, neutrophils, monocytes/ macrophages and mast cells; however, 
mesenchymal cells, including endothelium, smooth muscle and fibroblasts, are also able 
to do it if previously induced. Once activated and released from the cell, most of the 
inflammatory mediators have a short period of action, being quickly degraded or 
inactivated by enzymatic activity. Thus, there is a control and equilibrium system that 
regulates the inflammatory mediators activity (Kumar et al. 2009). On the other hand, 
plasma-derived mediators (e.g. complement proteins) are produced typically in the liver 
and are found as inactive precursors in circulation that must be activated by proteolysis, 
in order to acquire biological properties. 
 
 
 
Mediators Sources Action 
Cell-derived 
Cytokines 
 
TNF and 
Interleukins 
 
 
Chemokines 
 
Macrophages, 
endothelial cells, 
mast cells 
 
 
Leukocytes, activated 
macrophages 
 
Local endothelial activation (expression of 
adhesion molecules), 
fever/pain/anorexia/hypotension, 
decreased vascular resistance (shock) 
 
Chemotaxis, leukocyte activation 
 
 
Histamine Mast cells, basophils, 
platelets 
Vasodilation, increased vascular 
permeability, endothelial activation 
Serotonin Platelets Vasodilation, increased vascular 
permeability 
Prostaglandins Mast cells, leukocytes Vasodilation, pain, fever 
 
Leukotrienes 
 
Mast cells, leukocytes 
Increased vascular permeability, 
chemotaxis, leukocyte adhesion and 
activation 
Platelet-activating 
factor (PAF) 
Leukocytes, mast cells Vasodilation, increased vascular 
permeability, leukocyte adhesion, 
chemotaxis, degranulation, oxidative 
burst 
Reactive oxygen 
species (ROS) 
Leukocytes Killing of microbes, tissue damage 
Nitric oxide Endothelium, 
macrophages 
Vascular smooth muscle relaxation, 
microbes killing 
Table 1 – List of inflammatory mediators and their actions (adapted from Kumar et al. 2009). 
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Plasma protein-derived 
Complement 
products 
(C5a, C3a, C4a) 
 
 
 
Plasma (produced in 
liver) 
 
 
Leukocyte chemotaxis and activation, 
vasodilation (mast cell stimulation); 
Increased vascular permeability, smooth 
muscle contraction, vasodilation, pain; 
Endothelial activation, leukocyte 
recruitment 
 
Kinins 
 
Proteases 
activated during 
coagulation 
 
 
The complement system is composed by more than 20 proteins and proteases 
that are activated in cascade (Forneris, Wu, and Gros 2012). Usually, this system has 
performance in both innate (natural resistances with which a person is born – e.g. 
epithelial barriers, dendritic cells) and adaptive immunity (acquired over time – naturally 
or artificially; and passive or active) with regard to defense against microbial pathogens. 
Their activation leads to the formation of complement proteins cleavage products, that 
stimulate the vascular permeability, chemotaxis and opsonization - process of coating a 
particle, such as a microbe, to target it for phagocytosis (Kumar et al. 2009). The main 
functions of these components are showed in Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – The complement system. The complement system activation by classical, alternative or lectin 
pathways leading to breakdown products of C3 (the most abundant protein), which will trigger additional 
responses. All of these promote the formation of C3 convertase that convertes C3 into two functionally 
distinct fragments: C3a, which is released; and C3b, which is attached to the cell and, then, binds to the 
previously generated fragments to form C5 convertase, which in turn cleaves C5 to release C5a and leave C5b 
attached to the cell surface. C3a and C5a are the most important complement mediators of the inflammatory 
process. Functions of the several constituents involved are also indicated  (taken from Kumar et al. 2009). 
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Due to their importance in the inflammatory process, cytokines will be now 
discussed in further detail. 
 
1.1.3.1. Cytokines 
Cytokines are a family of small peptides, comprising interleukins (ILs), interferons, 
growth factors, chemokine family and tumour necrosis factor family (TNF). These 
molecules are produced by numerous cell types, mainly by activated lymphocytes and 
macrophages at sites of inflammation (Kumar et al. 2009). In the central nervous system 
(CNS) specific brain cells (including microglia and astrocytes) are responsible for cytokines 
production upon activation (Tuppo & Arias 2005; Tambuyzer et al. 2009) (Section 1.4.1.). 
These cell-derived mediators regulate the intensity and the duration of the immune 
response (Heneka 2006) and their levels are in general increased in the inflammatory 
states (Tuppo and Arias 2005). 
Until now, there is no unified cytokine classification system, with some authors 
including some interleukins in the chemokine family (e.g. IL-8) due to their functional 
properties. Moreover, some authors also categorize the cytokine class in two groups: pro-
inflammatory cytokines that are associated with inflammation progress and, 
consequently, with tissue damage (which under this categorization includes IL-8); while 
anti-inflammatory cytokines are responsible to limit inflammation, by preventing injurious 
events on the organism (Heneka and O’Banion 2007). 
In the present dissertation focus will be given to the interleukins and chemokines 
classes. 
 
 
1.1.3.1.1. Interleukins 
 
Currently, 37 interleukins have been identified and are numbered from 1 to 37, 
according to the order of their discovery. Thus, interleukins are a large group of 
immunomodulatory proteins that elicit a wide variety of responses in cells and tissues. 
These proteins bind to specific receptors located on cell surface, which act mainly on a 
paracrine or autocrine fashion. Depending on the ligands involved, particular signaling 
cascades can be activated, associated with growth modulation, differentiation and 
activation during an immune response. For instance, IL-1β is produced by several cells, 
including macrophages, monocytes, lymphocytes, microglia, neutrophils, fibroblasts, 
acting on T cells, fibroblasts, epithelial and endothelial cells, that in turn, induces pro-
inflammatory proteins, hematopoiesis and differentiation of T-helper cells. IL-6 is 
produced by endothelial cells, fibroblasts, monocytes/macrophages. This protein acts on 
hepatocytes, leukocytes, T cells and B cells, and promote the synthesis of acute phase 
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proteins, leukocytes activation, T cell differentiation and activation, B cell differentiation 
and production of immunoglobulins (Akdis et al. 2011). 
 
1.1.3.1.2. Chemokines 
Chemokines are small peptides that act as chemoattractants, playing a crucial role 
in cellular migration and intercellular communication in normal tissues but also during 
inflammation (Kumar et al. 2009; Tambuyzer et al. 2009). Some chemokines are produced 
transiently in response to inflammatory stimuli, leading to the leukocytes recruitment to 
the damaged sites, whereas other chemokines are constitutively produced in tissues 
(Kumar et al. 2009). 
The chemokine family consists of over 50 different molecules that confer 
chemotaxis, tissue extravasation, and modulation of leukocyte function during 
inflammation (Owens et al. 2005). These proteins can be divided into subfamilies on the 
basis of structural motifs. The CXC subclass of chemokines is considered one of the two 
major chemokine subfamilies and its members (e.g. IL-8) are primarily chemotactic for 
neutrophils and endothelial cells. The conserved glutamate–leucine– arginine (ELR) motif, 
within the receptor-binding domain of these proteins, distinguishes them from non-ELR 
CXC chemokines (such as IP-10), which primarily attract activated T cells (Strieter et al. 
1995). The CC chemokine subfamily usually contain four cysteines (a small number can 
contain six cysteines) and two N-terminal adjacent cysteine. This group includes MIP-1α, 
MCP-1, and RANTES, do not affect neutrophils but are chemotactic for 
monocytes/macrophages, T-lymphocytes, basophils and eosinophils. IL-8 is produced by 
monocytes, macrophages, neutrophils, lymphocytes, endothelial cells, epithelial cells and 
fibroblasts. It exerts chemotactic functions for neutrophils, NK cells, T cells, basophils and 
eosinophils (Akdis et al. 2011). Although this protein is designed as an IL, it has been 
recently renamed due to its chemotactic function as CXCL8. However, this term is not 
commonly used in the literature.  
Seven transmembrane, G-protein-coupled cell-surface receptors mediate the 
biological activities of chemokines and these receptors are named according to their 
chemokine subfamily classification. Until now or to date, five CXC receptors (CXCR1 to 
CXCR5) and nine CC receptors (CCR1 to CCR9) are known (Heneka and O’Banion 2007). 
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1.2. Neuroinflammation 
Neuroinflammation is a local tissue response to injurious stimuli in the CNS and is 
characterized by glial reactivity, induction of cytokines release, and vascular permeability. 
In this process the typical inflammatory features (redness, edema and pain) previously 
described does not occur. 
Regarding the brain defense against injuries or pathogens invasion, several 
inflammatory mechanisms are activated aiming the production of a variety of 
inflammatory mediators. These molecules are generated by brain cells previously 
activated, including microglia, astrocytes and neurons. The inflammatory process may 
pass to a longer term chronic phase (Section 1.6.) and impact on CNS functions. Indeed, 
chronic inflammation can be a key factor in the development of neurodegenerative 
diseases, among which AD, multiple sclerosis, Parkinson's disease, Huntington's disease 
(HD), amyotrophic lateral sclerosis (Frank-Cannon et al. 2009; Graeber, Li, and Rodriguez 
2011). 
 
1.2.1. Cellular and molecular mediators 
Several molecular mediators are involved in neuroinflammation, mainly cytokines, 
which are produced by activated brain cells. As mentioned, these molecules play an 
important role in neurodegenerative diseases, promoting inflammatory processes in CNS. 
There are evidences that inflammatory cytokines and others molecules such as the 
complement system proteins, appear to play significant roles in the neuroinflammatory 
process (Reale et al. 2010). The mechanisms underlying to cytokines involvement will be 
further detailed, in particular to AD, in Section 1.3. 
Microglia are the resident immune cells of the brain that support and protect 
neuronal functions. They are derived from monocyte precursor cells during 
embryogenesis, constitute around 10% of the cells in the nervous system, and represent 
the first line of defense against any brain tissue injury (Sastre et al. 2006; Tambuyzer et al. 
2009; Rubio-Perez & Morillas-Ruiz 2012; Meraz-Ríos et al. 2013). Although microglia have 
neuroprotective and phagocytic functions, they can also have neurotoxic effects (Lee et 
al. 2010) when overstimulated. They are present in the CNS, where the white matter 
generally contains fewer microglia than the gray matter (Tambuyzer et al. 2009). In the 
absence of brain injury, microglial cells are in the inactive state and exhibit a small soma 
with branching processes presenting a resting ramified phenotype. Under pathological 
conditions (neurodegenerative disease, stroke and tumor invasion) they become 
activated undergoing several morphological changes, acquiring amoeboid form, 
decreased branching and increased soma growth, displaying a wide variety of specific 
cellular surface markers (Tambuyzer et al. 2009; Meraz-Ríos et al. 2013). 
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According to several authors, in addition to microglia, also peripheral 
macrophages are also able to perform phagocytosis and initiate innate immune response 
(Rezai-Zadeh et al. 2009; Gate et al. 2010). Their recruitment into the CNS is made by the 
release of specific cytokines during microglial and astrocytic activation, being able to cross 
the undisrupted blood-brain barrier (BBB). 
Both microglia and macrophages, recognize foreign substances and pathogens 
through pattern recognition receptors (PRRs). Toll-like receptors (TLRs), nucleotide-
oligomerization binding domain (NOD) proteins and C-type lectin receptors are included 
in the PRRs class. The interaction between these receptors and pathogen-associated 
molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) promotes 
the beginning of the cellular defense mechanisms (Sterka & Marriott 2006; Rubartelli & 
Lotze 2007), which lead to production and release of pro-inflammatory cytokines (as IL-
1β, IL-6, TNF-α, and INF-γ (interferon-γ)), chemokines (IL-8; RANTES-regulated on 
activation, normal T cell expressed and secreted; MCP-1-monocyte chemoattractant 
protein-1; MIP-1α and β - macrophage inflammatory protein-1), reactive oxygen species 
(ROS) and complement factors (C1q, C3, C4 and C9). These compounds contribute to 
neuronal dysfunction and cell death, promoting a vicious cycle (Lee et al. 2010; Meraz-
Ríos et al. 2013). Additionally, microglia also express receptors for advanced glycosylation 
end products (RAGE), several types of scavenger receptors, among others (Okun, 
Mattson, and Arumugam 2010). 
Astrocytes are the most abundant glial cells present in the CNS and have several 
functional capacities, being responsible for brain organization and maintenance 
(Sofroniew and Vinters 2010). In addition, they provide biochemical support to the 
endothelial cells of the BBB, supply nutrients to the nervous tissue, maintain the ion 
balance, restore the brain and spinal cord when they suffer injuries and provide trophic 
support to neurons (Lee et al. 2010). During brain inflammatory process astrocytes can 
also produce and secrete pro-inflammatory mediators and have been proposed to 
contribute to neuropathology underlying cognitive deficits. 
Recent evidences demonstrate that neurons, by themselves, can generate 
inflammatory molecules, being a source of complement molecules, cyclooxygenases 2 
(COX2)-derived prostanoids, inducible nitric oxide synthase (iNOS), C-reactive protein, 
amyloid P, pentraxins, macrophage colony-stimulating factor, and cytokines such as IL-1β, 
IL-6 and TNF-α. Additionally, neurons have been reported to secrete cluster of 
differentiation 22 (CD22), which inhibits the production of pro-inflammatory cytokines by 
microglia (Lee et al. 2010). The chemokines produced by neurons can work as messengers 
between neurons and glial cells, aiding in intracellular brain communication processes 
(Haass & Selkoe 2007; Biber et al. 2008).  
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1.3. Dementia: focus on Alzheimer’s disease 
Dementia, a syndrome usually associated with many causes, is characterized by a 
progressive loss of intellectual and cognitive functions that impairs the successful 
performance of daily living activities. It is most frequent in the developed world and is 
becoming even more so as a consequence of life span increase, thus contributing to an 
augmented risk of the elderly population suffering from dementia. Among the clinical 
symptoms, memory is the most common cognitive ability lost with dementia, affecting 
10% of people aged over 70 years and 20-40% of individuals aged over 85 years. In 
addition to memory, other mental faculties are also affected, such as language, 
visuospatial ability, calculation, judgment and problem solving. Neuropsychiatric and 
behavioral alterations are also present in many cases of dementia, resulting in 
depression, agitation, insomnia, hallucinations and disinhibition (Bird and Miller 2010). 
Treatment is generally supportive or directed at relieving symptoms, and is usually far 
from perfect. Dementia is now an area of intense scientific study, which brings the 
perspective of more effective therapies and adequate treatments for the different 
dementia types in the future. 
Recognizing dementia is easy if clinical symptoms are severe, which are normally 
associated with the late stages of disease. However, it is much harder to distinguish early 
dementia from the forgetfulness due to anxiety or from the mild cognitive impairment 
(MCI), that often accompanies ageing (usually affecting memory for names and recent 
events), and does not necessarily progress to more severe disability (Wilkinson and 
Lennox 2005). Also, alterations of multiple capacities usually distinguish dementia from 
other disorders, such as amnesia and aphasia, which affect a single functional domain 
(memory and language, respectively).  
Most forms of dementia are progressive in nature, increasing in severity over time. 
The age of onset and the progression rate of symptoms differ among the major 
dementing disorders. Most have an insidious onset and develop slowly, sometimes over a 
period of many years, even before clinical manifestation of the symptoms. These include 
pathologies such as AD, HD and frontotemporal dementia (FTD).  
In Europe, 7,3 million citizens suffer from dementing disorders and in Portugal 
over 153.000 people are affected. As life span is increasing, specialists predict that this 
value will duplicate in 2040 (http://www.alzheimerportugal.org). Presently, estimates 
indicate that there are nearly 36 million people with dementia worldwide 
(http://alzheimers.org.uk). Approximately 1% of the population is affected at age of 60-65 
years, rising to 10–35% in those over 85 years old. Of the patients with late onset 
dementia (>65 years), about half have AD, 16% Vascular dementia and 30% other forms 
of dementia, such as dementia with Lewy bodies (DLB) and FTD (Lobo et al. 2000). In 
particular, for the Portuguese population, AD was also one of the most common forms of 
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dementia in a study realized in rural and urban areas from Northern of Portugal (Nunes et 
al. 2010). 
AD was firstly described by the German psychiatrist and neuropathologist Alois 
Alzheimer in 1907 (Lee et al. 2010; Rubio-Perez & Morillas-Ruiz 2012). It is the most 
common form of dementia (50 to 75% of all cases) and age-dependent 
neurodegenerative disorder (Lee et al. 2010; Davinelli et al. 2011; Meraz-Ríos et al. 2013). 
It is often considered a multifactorial disease involving multiple molecular mechanisms 
(Davinelli et al. 2011).  
Clinical signs suggestive of AD pathology include gradual memory loss, progressive 
cognitive impairment, decline of spatial and temporal orientation, loss of acquired skills, 
and emotional and behavioral disturbances (Glass et al. 2010; Lee et al. 2010). After a few 
years, approximately 5, all aspects of intellectual function are affected and the patient 
become frail and unsteady, generally requiring a full-time caregiver. Pneumonia is the 
principal cause of death in these patients (Castellani, Rolston, and Smith 2010). Recently, 
it has been suggested that the pathological process of AD initiates decades before the 
appearance of typical symptoms (Kim et al. 2011), and, generally, the clinical duration of 
the disease is around 8 to 10 years. It is estimated that AD affects around 27 million 
worldwide, 7-8 million in Europe, 90.000 individuals in Portugal (Rubio-Perez & Morillas-
Ruiz 2012; http://www.alzheimerportugal.org). Approximately 8.4% of the AD patients 
have around 85 years or more, representing a growing public health problem as life 
expectancy increases (Davinelli et al. 2011).  
 
1.3.1. AD molecular basis and histopathological alterations 
Extracellular senile plaques (SP) and intracellular neurofibrillary tangles (NFT) are 
the two major neuropathological hallmarks of AD (Figure 4) (Tavee & Sweeney 2010; 
Davinelli et al. 2011). Brain autopsy of typical AD patients reveals these lesions and 
macroscopic cerebral atrophy (reduction of brain volume), as a cause of neuronal and 
synapse degeneration (Heneka 2006; Lee et al. 2010). Usually, these lesions are present in 
specific brain regions implicated in learning and memory processes, such as temporal, 
parietal and frontal cortex as well as the hippocampus and amygdala. The affection of 
these areas, can explain in part the clinical symptoms observed in AD patients (Heneka 
2006). Indeed, the presence and distribution of the NFT, SP and synaptic degeneration 
correlates with the degree of cognitive decline (Shankar and Walsh 2009). Other 
pathologic events such as, reactive gliosis, microglial activation, and neuroinflammation 
(Section 1.3) are also found in AD brains. 
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1.3.1.1. Senile plaques 
SP (Figure 4 A.) are extracellular deposits mainly composed by aggregates of 
amyloid β (Aβ), which is a peptide that derives from the proteolitic cleavage of the 
Alzheimer´s Amyloid Precursor Protein (APP). APP can suffer proteolitic cleavage by the 
amyloidogenic or non-amyloidogenic pathways. In the amyloidogenic processing (Figure 
5) Aβ is produced, by the sequential cleavage of APP by β-secretase (mainly beta-site APP 
cleaving enzyme 1 (BACE1) in neurons) and the γ-secretase complex  (Heneka 2006; 
Benton 2011; Davinelli et al. 2011); while in the non-amyloidogenic pathway α-secretase 
precludes Aβ formation  (O’Brien and Wong 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
Figure 4 – Neuropathological hallmarks of AD. A. Senile Plaques (SP) mainly composed of aggregates of 
amyloid-β peptides (silver stained); B. Neurofibrillary Tangles (NFT) inside the neurons, resulting from 
Tau protein hyperphosphorylation (silver stained) (taken from Tavee & Sweeney 2010). 
Figure 5 - APP processing and Aβ accumulation. APP can be cleaved by two different pathways. In the non-
amyloidogenic pathway α-secretase originates sAPPα and C83, and the small peptide p3. In the amyloidogenic 
pathway β-secretase generates sAPPβ and C99. C99 is a substrate for γ-secretase, generating Aβ and, 
consequently, their accumulation in senile plaques (adapted from Zhang 2012). 
 
Cytosol 
Extracellular 
Non-Amyloidogenic Pathway Amyloidogenic Pathway 
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Aβ40 and Aβ42 are the most common forms of Aβ, which are constituted by 40 or 
42 amino acids, respectively (Heneka 2006). The Aβ42 peptide is less soluble, has higher 
propensity to form aggregates and is more neurotoxic relatively to Aβ40. Of note, factors 
affecting normal APP processing, including abnormal phosphorylation, oxidative stress 
and Aβ itself, can contribute to abnormal Aβ production (Rebelo et al. 2007; Henriques et 
al. 2010).  
Several studies support the amyloid hypothesis, which states that increased Aβ 
production and accumulation is the first event that triggers a pathogenic cascade that will 
lead to synaptic dysfunction, abnormal protein phosphorylation, apoptosis, oxidative 
stress and inflammation processes. As a consequence, neuronal function is affected, 
culminating in neurodegeneration typical of AD (Masters et al. 2006; Jakob-Roetne & 
Jacobsen 2009; Chow et al. 2010).  In accordance with this theory, genetics, age and 
environmental factors can contribute to the imbalance between Aβ production and its 
clearance.   
 
1.3.1.2. Neurofibrillary Tangles 
NFT consist of intraneuronal aggregates of hyperphosphorylated forms of Tau 
protein (Figure 4 B.) (Heneka 2006; Glass et al. 2010). Tau is a microtubule-associated 
protein, that interacts with cytoskeleton proteins (such as actin) promoting microtubule 
assembly and stability, as well as regulating the intracellular vesicles and organelle traffic. 
In AD, the abnormal phosphorylation of Tau and their dissociation from microtubules 
leads to their breakdown into NFT and paired helical filaments (PHF) (Benton 2011), 
which in turn results in neuronal degeneration (Davinelli et al. 2011). With the 
disturbance of the tau-microtubule binding equilibrium, there is a resulting increase in 
the cytosolic unbound levels of tau as well, and consequently an increased likelihood of 
protein misfolding and subsequent aggregation as neuropil threads in dystrophic neuritis 
and as neurofibrillary tangles (Craig-Schapiro, Fagan, and Holtzman 2009). This fact could 
explain Tau increased levels found in CSF, since this protein is released from degenerating 
neurons and subsequent diffusion into this biological fluid.  
In essence, alterations in the signaling cascades that lead to abnormal proteins 
phosphorylation or aggregation can potentially contribute to both SP and NFT formation.  
These alterations will interfere with normal neuronal function and integrity leading to 
degeneration typical of AD. Both histopathological alterations are related with the disease 
clinical manifestations progression as shown in Figure 6 (Citron 2004; Craig-Schapiro et al. 
2009; Jakob-Roetne & Jacobsen 2009). 
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At preclinical AD stage there is already an abrupt increase of amyloid plaques 
formation, in contrast with a prompt decrease of neuronal integrity. However, at this 
phase AD pathology cannot be diagnosed since there are no clinical symptoms 
manifestations. It is only, in advanced phases when the severity of neurodegeneration 
already took place and the clinical symptoms manifestations are already evident, that AD 
can be detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.3.2. Genetic basis and risk factors of Alzheimer’s disease 
Although the etiology of AD remains unclear, various risk factors have been 
associated with the disease, including genetic (mutation and polymorphisms), biologic 
and environmental factors. AD can be classified into two forms: early-onset AD (EOAD) 
and late-onset AD (LOAD). 
In the EOAD, clinical symptoms start before 65 years. It represents less than 5% of 
all AD cases and is associated with hereditary genetic factors. APP, Presenilin 1 (PSEN1) 
and Presenilin 2 (PSEN 2) have been genetic factors involved in AD (Davinelli et al. 2011),  
which are located in different chromosomes while PSEN1 and PSEN2 are localized on 
chromosome 14 and 1, respectively. APP is localized in chromosome 21, explaining  why 
individuals with trisomy 21 have a higher risk to develop AD (Thinakaran and Koo 2008). 
These mutations share a common biochemical pathogenic pathway, converging on 
Figure 6 - Relationship between the neuropathology development and clinical changes of AD 
(taken from Craig-Schapiro et al. 2009).  
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increased Aβ peptide production, in particular the Aβ42 form (Citron et al. 1997; Davinelli 
et al. 2011; De Strooper, Iwatsubo, and Wolfe 2012). 
On the other hand, LOAD is the most common form of AD affecting individuals 
over 65 years old. It has a sporadic origin and accounts for more than 95% of the total 
cases, which in time are triggered by normal aging neurodegeneration and diverse 
genetic and environmental risk factors. In this form, onset and progression of disease are 
insidious. 
Other factors have also been associated with sporadic cases such as decreased 
brain capacity and reduced mental and physical activity during life (Gatz et al. 2006). As 
mentioned, sporadic cases of AD can also be associated with increased genetic 
susceptibility to develop the disease, being the most well documented risk factor the 
Apolipoprotein E gene (APOE). The ε2, ε3 and ε4 are the majors allelic variants of this 
protein and several studies have demonstrated that the APOE ε4 allele is the strongest 
genetic risk factor to AD development, since it is related, for instance, with increased 
propensity for Aβ aggregation (Herukka et al. 2007; Davinelli et al. 2011; Ryu et al. 2012). 
The comprehension of the molecular mechanisms underlying the disease 
pathogenesis are useful not only to understand the genetic cases but also the sporadic 
form, since increased Aβ production and accumulation into SP is a common feature in 
both cases. 
 
1.3.3. AD diagnosis: clinical, neurochemical and genetics 
The clinical and pathological overlap among neurodegenerative disorders 
represents a challenge to diagnosis specificity (Reilly et al. 2010). In order to overcome 
misdiagnosis of dementia, cognitive evaluation tests (for exclusion of other dementias), 
neuroimaging exams, and genetic testing can be carried out. More recently, a 
neurochemical-based diagnosis consisting on the evaluation of a triplet of CSF biomarkers 
has been used in many European countries. The later can assist clinical evaluation and 
improve differential diagnosis of dementia, in particular AD from other forms of dementia 
(Craig-Schapiro et al. 2009; Lewczuk et al. 2009; Zetterberg et al. 2010). 
The clinical diagnosis comprises cognitive and behavior assessment, in which the 
attention, concentration, language, memory and learning skills are evaluated. Mini 
mental (MM) is a commonly used questionnaire to evaluate the cognition and functional 
status, to check the existence of cognitive impairment and to monitor disease 
development (McKhann et al. 1984; O’Bryant et al. 2008; Eschweiler et al. 2010). It is an 
easily performed 30-point test that contains orientation, working memory (e.g., spell 
world backwards), episodic memory (orientation and recall), language comprehension, 
naming and copying tests (Eschweiler et al. 2010). However, this clinical diagnosis is not 
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100% conclusive requiring supplementary exams to improve diagnostic accuracy 
relatively to cognitive evaluation.  
Several neuroimaging tests such as magnetic resonance imaging (MRI), single 
photon emission computerized tomography (SPECT) and positron emission tomography 
(PET) are applyied, providing relevant clinical results. The MRI presents higher resolution 
without exposing the patient to ionizing radiation, being useful to rule out other 
conditions that may cause symptoms similar to AD, detecting tumors, evidence of small 
or large strokes, damage from severe head trauma or a buildup of fluid in the brain 
(Frisoni et al. 2010). The techniques of SPECT and PET are able to study the cerebral 
perfusion and to measure brain energy metabolism. More recently, both PET and SPECT 
have been used to quantify Aβ in the brain taking advantage of the chemical Pittsburgh 
Compound-B (Klunk et al. 2004; Davinelli et al. 2011; Tartaglia et al. 2011). Nonetheless, 
many of these tests detect late features of AD, as brain atrophy of specific regions, when 
histopathological alterations are already present and cognitive impairment is already 
evident. 
With regard to neurochemical diagnosis of AD, it has been identified and 
established a panel of biomarkers found in patients’ CSF (Craig-Schapiro et al. 2009). CSF 
is in direct contact with the CNS, thus it becomes a favorable body fluid to be used in 
dementia diagnosis since it can reflect the biochemical and metabolic changes during the 
course of a neurological disease. Aβ42, Phospho-Tau (P-Tau) and Total-Tau (T-tau) are the 
main altered biomarkers found in CSF of MCI or AD patients. The decreased Aβ42 levels in 
CSF were related to the amyloid accumulation in the brain and the increase in P-Tau and 
T-Tau levels were related to neuronal damage or degeneration (Craig-Schapiro et al. 
2009; Grimmer et al. 2009; Hampel et al. 2010; Paternicò et al. 2012). The combined use 
of Aβ42, P-Tau and T-Tau CSF levels improves distinction between different forms of 
dementia and, in addition, are useful to predict the conversion from MCI to AD with 
elevated sensitivity and specificity (Craig-Schapiro et al. 2009; Davinelli et al. 2011). 
Patients with MCI have an elevated risk to develop AD (Risacher et al. 2009; Kester et al. 
2011). Thus, evaluation of CSF biomarkers can be helpful for detection of patients with 
progressive disorder. However, as the later panel of neurochemical biomarkers requires 
CSF collection by lumbar puncture which is an invasive process (Davinelli et al. 2011; 
Kroksveen et al. 2011), many studies are also focusing on the identification and validation 
of more peripheral biomarkers. Additionally to CSF biomarkers, also atrophy of medial 
temporal structures, genetic risk factors, such as APOE ε4 and the presence of SP have 
been seen as strong predictive factors of the progression from MCI to AD. Therefore, all 
these factors together may allow an early AD diagnosis, preventing or delaying the 
dramatic consequences of this disease (Herukka et al. 2007; Craig-Schapiro et al. 2009).  
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Relatively to the genetic diagnosis, as previously mentioned, some mutations 
were identified in different genes that are directly related to AD. To evaluate the genetic 
risk to develop AD, genetic approaches may be of benefit in suspected familial forms of 
dementia, in particular when a highly penetrant gene mutation is inherited in an 
autossomal dominant pattern. In this situation, genetic testing may be an advantage since 
the identification of the specific mutations in affected family members will confirm the 
dementia diagnosis (Atkins and Panegyres 2011), and may help in the delay of AD 
symptoms. However, as these usually represent a minor part of the total cases of AD, 
genetic testing is not a routinely used diagnostic tool, and less so for ApoE4 which is only 
considered a genetic risk factor for AD. 
Nowadays, there is no cure for AD, thus all efforts are directed for improving the 
sensitivity and specificity of the diagnostic tools, and in developing new tools that would 
allow early diagnosis, a stage where the existence drugs could be more effective in 
delying the disease progression. Presently, AD diagnosis is performed in basis of detailed 
clinical history, cognition and functional status assessment, neuroimaging, and in 
laboratory testing (Biasutti et al. 2012).  
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1.4. Neuroinflammation in Alzheimer’s disease 
The inflammatory process has a fundamental role in pathogenesis of AD, in which 
signs of chronic neuroinflammation and altered levels of some cytokines have been 
reported (Frank-Cannon et al. 2009; Kim et al. 2011; Leung et al. 2013). In this pathology, 
the presence of SP and NFT is able to trigger a series of cellular events which culminate in 
an inflammatory response mediated by activated microglia and reactive astrocytes 
(Figure 7), in an attempt to clear the injurious components (Rojo et al. 2008; Frank-
Cannon et al. 2009; Meraz-Ríos et al. 2013). These activated inflammatory cells are found 
near neurons, surrounding extracellular SP, and are capable of up-regulating certain pro-
inflammatory mediators such as cytokines, chemokines, complement molecules, among 
other molecules which could promote neuronal dysfunction and, consequently, neuronal 
death (Rubio-Perez and Morillas-Ruiz 2012). Additionally, it also has been described 
numerous interactions between cytokines and SP components that can create vicious 
cycles, contributing to pathology development (Rubio-Perez and Morillas-Ruiz 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Neuroinflammation process in AD. The Aβ aggregates promote microglia activation through 
TLRs and RAGE receptors. These receptors activate NF-kB and AP-1 transcription factors inducing the 
production of ROS and the expression of inflammatory cytokines such as IL-1, IL-6 and TNFα. These 
inflammatory compounds act on the neurons and stimulate the astrocytes, which amplify the pro-
inflammatory responses, promoting neurotoxic effects. Adhesion molecules and chemokines are also 
produced, being responsible for the recruitment of peripheral immune cells. NFkB - nuclear factor-kappa 
B- dependent pathway; AP-1 – activator protein 1. (taken from Meraz-Ríos et al. 2013).  
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Initially, the inflammatory responses (mediated by pro-inflammatory mediators) 
are beneficial and necessary to prevent the neurotoxicity caused by the amyloid 
fragments. However, the anti-inflammatory components are also important in order to 
resolve the initial inflammatory response limiting the disease process. The persistent glial 
cells activation leads to chronic neuroinflammation that can contribute to disease 
progression and hastening of neuronal demise (Frank-Cannon et al. 2009). 
 
1.4.1. Cellular and molecular inflammatory mediators in AD 
Although, studies have proposed a role for the complement system in molecular 
mechanisms of neuroinflammation in AD (Shen & Meri 2003; Bohlson et al. 2007; Bénard 
et al. 2008; Maier et al. 2008; Ager et al. 2010), in this work emphasizes will be given to 
the role of inflammatory cytokines in this pathology. 
Aβ induces microglia and astrocytes activation. Activated microglia (Figure 7) leads 
to increased expression of cell surface molecules of the major histocompatibility complex. 
Then, the adhesion of microglia to Aβ aggregates is mediated by scavenger receptors on 
cell surface, as TLRs and RAGE receptors (Lee et al. 2010; Meraz-Ríos et al. 2013). This 
binding induces the activation of extracellular signal-regulated kinases (ERK) and mitogen-
activated protein kinases (MAPK) pathways, leading to pro-inflammatory genes 
expression and to the production of cytokines and chemokines (Sastre et al. 2006; Heneka 
& O’Banion 2007; Rubio-Perez & Morillas-Ruiz 2012). Among those are IL-1 and IL-6 but 
also IL-8, MCP-1 and RANTES. 
Microglia can play a beneficial role against AD, since its activation reduces Aβ 
accumulation by increasing its phagocytosis, clearance and degradation. Additionally, 
they secrete soluble factors, such as glial-derived neutrophic factor (GDNF), which has 
been demonstrated to be beneficial for neurons survival (Heneka & O’Banion 2007; 
Rubio-Perez & Morillas-Ruiz 2012). 
Astrocytes also provide a protective barrier between Aβ deposits and neurons, 
playing an important role in Aβ clearance and degradation (Sastre et al. 2006; Rubio-
Perez & Morillas-Ruiz 2012). Similar to microglia, astrocytes are activated by Aβ 
aggregates through TLRs and RAGE-dependent pathways and also produce and secrete a 
variety of pro-inflammatory molecules. The presence of Aβ42 inside of astrocytes is a 
consequence of the phagocytosis of local degenerated dendrites and synapses (Sastre et 
al. 2006; Meraz-Ríos et al. 2013). However, under certain conditions related to chronic 
stress, the intense activation of microglia and astrocytes may not be beneficial, 
prolonging neuroinflammation and contributing to neurotoxicity mediated by expression 
of inflammatory mediators, such as iNOS, ROS, NO (Heneka and O’Banion 2007; Meraz-
Ríos et al. 2013). Recently, it has been proposed that astrocytes could also be a source of 
Aβ, because they overexpress the APP β-secretase in response to chronic stress (Rossner 
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et al. 2005). Hence, under stress conditions, astrocytes can potentially exacerbate 
neuronal damage and accelerate disease progression by intensifying neuronal death due 
to increasing Aβ production. 
Aβ leads to increased levels of cytokines, including IL-1β, IL-6, TNF-α, MIP-1α and 
MCP-1 upon microglia activation (Meda et al. 1999; Sastre et al. 2006). In addition, Aβ 
was also able to stimulate NFkB, which is necessary for cytokine production. Pro-
inflammatory factors produced by neurons can also contribute to neuronal damage and, 
consequently, to AD pathogenesis by triggering neuroinflammatory processes; 
nevertheless, neuronal generation of TNF-α and low concentrations of NO, may be 
considered a defense mechanism against local inflammatory reactions, since they confer 
neuroprotection (Heneka and O’Banion 2007). Therefore, the function of these brain 
neuroimmune modulators oscillates between neuroprotective and neurodegeneration 
effects, depending on the AD stage. 
In a chronic stage, the continued release of many of these molecules mediators, 
may also impact on AD by affecting APP expression, and processing, Aβ deposition, Tau 
phosphorylation, NFT formation and neurodegeneration. 
For instance, in vitro studies showed that IL-1β is able to activate the MAPK-p38 
pathway which can phosphorylates Tau protein (Li et al. 2003; Rojo et al. 2008). Further, 
both interleukins were shown to affect up-regulate activity of the Ciclin-dependent kinase 
(CdK)5/p35 complex, the main protein kinase involved in Tau phosphorylation process 
(Rojo et al. 2008). More recently, Kitazawa and their colleagues (2011) reported that the 
inhibition of IL-1β signaling in AD animal models decreased the activity of cdk5/p25 but 
also of glycogen synthase kinase (GSK)-3β, and p38-MAPK, leading to decreased P-Tau 
levels. Moreover, it was shown that IL-1β could be involved in increasing APP non-
amyloidogenic cleavage, therefore decreasing Aβ production, due to α-secretase up-
regulation (Tachida et al. 2008). Further, recent studies have shown that this cytokine can 
induce Aβ removal, suggesting a neuroprotective role for IL-1β in AD neuropathogenesis 
(Matousek et al. 2012). 
IL-6 was overexpressed in brains of APP transgenic models, causing significant 
gliosis and decreasing Aβ deposition in vivo this was corroborated by the up-regulation of 
the glial phagocytic marker and stimulation of microglial phagocytosis of Aβ. Additionally, 
IL-6-induced neuroinflammation did not affect the APP processing in the transgenic 
models tested, suggesting a beneficial role of reactive gliosis by promoting Aβ clearance 
in early stages of AD (Chakrabarty et al. 2010). 
IL-8 is an important chemokine for the recruitment of activated microglia to 
damage brain sites. IL-8 receptors are located in dystrophic neurites indicating that this 
chemokine is able to establish glial interactions with neurons and, thereby, contribute to 
neuronal damage (Kim et al. 2011) by excreting its pro-inflammatory actions. 
Alternatively, IL-8 can have a protective role against Aβ-induced neurotoxicity, by 
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stimulating the increase of brain-derived neurotrophic factors levels in human neurons 
(Ashutosh et al. 2011) 
Further, oxidative stress induced by Aβ, can up-regulate RANTES expression in rat 
brain endothelial cells.  Since, neurons treated with RANTES demonstrated increased cell 
survival by the increased in RANTES levels, may suggest a beneficial effect in AD 
neuroinflammation. However, how RANTES exerts its neuroprotective effects remain 
unclear (Tripathy et al. 2010). 
 
1.4.2. Cytokine levels in AD 
The levels of cytokines and other proteins associated with inflammatory processes 
have been extensively investigated of AD patients’ blood and CSF to uncover mechanisms 
of neuroinflammation either in dementia or in the context of biomarker research. 
However, the studies that addressed the levels of the above mentioned molecular 
mediators in patient tissues and peripheral body fluids are controversial (For review see 
Brosseron et al. 2014). We will give emphasis to the interleukins and chemokines 
adreessed in our study. 
 
o IL-1β – IL-1β levels were reported to be elevated in CSF of AD patients in 
comparison to controls, and unchanged in plasma samples of the same individuals 
(Blum-Degen et al. 1995). In contrast to this study, the plasma levels of IL-1β were 
found increased in AD patients (Licastro et al. 2000). In agreement, more recently 
IL-1β levels were shown to be increased in serum samples of MCI and AD patients 
comparatively to control subjects (Forlenza et al. 2009). Although there are still 
inconsistent data regarding to IL-1β levels, no study revealed down-regulation of 
this interleukin in AD pathology (for Review see Brosseron et al. 2014). 
 
o IL-6 – The levels of IL-6 were also measured in CSF and plasma samples. Similar to 
IL-1β, IL-6 levels in CSF were reported to be increased in AD patients while plasma 
levels were not significantly affected when compared to healthy individuals (Blum-
Degen et al. 1995). Controversially, according to Kálmán et al. (1997), no changes 
could be detected for CSF of MCI and AD patients. Severe AD patients showed 
higher IL-6 levels comparatively to less severe AD and controls subjects. 
Moreover, serum IL-6 levels correlate with the severity of dementia in Down 
syndrome and in AD (Kálmán et al. 1997). IL-6 plasma levels were also found 
increased in patients with AD comparatively to controls (Licastro et al. 2000). 
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For both interleukins, the literature data is not consensual and additional studies 
should be carried out. Nonetheless, since several findings indicate that the plasma levels 
of IL-1β as well as IL-6 are altered in AD, the detection of these molecules, along with 
others, and the correct definition of their pattern might be useful for the monitoring of 
brain inflammation associated with AD (Blum-Degen et al. 1995; Licastro et al. 2000; 
Forlenza et al. 2009). 
Chemokines are physiologically generated at basal levels in the healthy CNS, and 
recent studies have focused in their role, expression and receptors in neurodegenerative 
diseases, including in the AD associated neuroinflammation. As mentioned, chemokines 
are typically produced by microglia and astrocytes, while their receptors are present in 
neurons. This fact promotes the communication between glial cells and neurons 
establishing a local inflammatory response that could favor the Aβ phagocytosis in AD 
early stages (reviewed in Zilka et al. 2012). Nevertheless, in chronic inflammation, as is 
the case for AD, increased chemotaxis of the phagocytic cells is observed resulting in 
increased microglial recruitment around Aβ deposition, which can prompt neuronal 
demise (Sastre et al. 2006). Aβ stimulate chemokine release not only in microglia but also 
in astrocytes, neurons, and monocytes (Meda et al. 1999; Streit et al. 2001; Sastre et al. 
2006; Ashutosh et al. 2011). 
In particular, up-regulation of several chemokines, such as IL-8, MCP-1, RANTES, 
and MIP-1 (both α and β types), as well as chemokine receptors in CSF of AD patients 
were shown. However, in plasma samples, the reports showed no consensual results 
(Table 2). 
 
o IL-8 – It has been found increased in the CNS, in particular in the CSF and brain 
tissue of AD patients relative to controls. Contrary to the increases observed for 
this chemokine in the CSF of both MCI and AD patients, circulating plasma IL-8 
levels decreased for both patients (MCI and AD) in comparison to control 
individuals (Kim et al. 2011). Nonetheless, some studies also report that plasma IL-
8 levels do not change in AD (Leung et al. 2013). 
 
o MCP-1 (also named CCL2) – It was reported that plasma MCP-1 levels were 
unchanged when comparing controls and AD patients while increases of this 
chemokine were detected in CSF of AD patients. The increases in CSF levels 
correlated with cognitive decline (Westin et al. 2012).  Alternatively, decreased 
plasma levels of this chemokine in AD patients relatively to healthy individuals 
were recently reported (Reale et al. 2012). Moreover, differences arise for MCI 
and early versus severe AD cases. MCP-1 levels were found significantly increased 
in plasma of MCI and mild AD patients but not in severe AD cases in comparison to 
controls (Kim et al. 2011). Consistently, elevated MCP-1 levels were also detected 
in serum samples of both MCI and early AD patients while lower levels were 
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reported for severe AD cases (Galimberti et al. 2006). These findings suggested 
that MCP-1 plasma/serum levels could be a useful biomarker to monitor the 
inflammatory process in AD.  
 
o RANTES (also named CCL5) –RANTES showed elevated expression in  the cerebral 
microcirculation of AD patients (Tripathy et al. 2010) and increased levels in 
peripheral biological fluids in AD (Reale et al. 2012). However decreases in mRNA 
expression of this chemokine in AD blood samples were also reported (Kester et 
al. 2012).  
 
Table 2 summarizes the changes of these cytokines in different peripheral fluids and 
AD brains (for review see Brosseron et al. 2014). 
 
 
 
 
 
In essence, cytokines are important to trigger immune response in CNS, being 
responsible for recruitment of microglia and astrocytes to the site of Aβ deposition 
releasing molecular inflammatory mediators and defining the extension of local 
inflammation. However, in general it has been proposed that their chronic production in 
advanced AD could be harmful and contributes to neuronal death. Controversial results 
still exist regarding the function, the effect and the levels of the mentioned cytokines in 
 Plasma CSF AD brains References 
Interleukins 
IL-1β 
 
 
 
  (Blum-Degen et al. 1995; Licastro et al. 
2000; Grammas and Ovase 2001; 
Forlenza et al. 2009; Leung et al. 2013) 
 
IL-6 
 
 
 
  (Bauer et al. 1991; Blum-Degen et al. 
1995;  Kálmán et al. 1997; Licastro et al. 
2000; Grammas and Ovase 2001) 
Chemokines 
IL-8 
 
 
 
  (Ashutosh et al. 2011; Kim et al. 2011; 
Leung et al. 2013) 
 
MCP-1 
 
 
 
  (Grammas and Ovase 2001; Galimberti et 
al. 2006; Kim et al. 2011; Westin et al. 
2012; Leung et al. 2013) 
 
RANTES 
 
 
 
 
    - 
 (Tripathy et al. 2010; Kester et al. 2012; 
Reale et al. 2012) 
Table 2 – Detection of cytokines levels in plasma, CSF and AD brains.  
= 
= 
= 
= 
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AD neuroinflammation. These discrepancies could be related with inter-individual 
variances, collecting and processing of biological samples, lack of patients collective 
characterization and differences between the technical approaches of the studies. Hence, 
additional studies are needed to improve our knowledge in this field and to discover 
reliable inflammatory biomarkers for AD. 
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II.   Aims of the Thesis
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AD is a complex neurodegenerative disorder neuropathologically characterized by 
the presence of SP and NFT, synaptic loss and consequently neurodegeneration. The Aβ 
peptide is the major constituent of SP and plays a crucial role in AD pathology. Increased 
Aβ production and aggregation was associated with a series of pathogenic processes, 
which include, among others, activation of inflammatory responses that will contribute to 
neurodegeneration and potentially to gradual cognitive decline. Microglia are activated 
by Aβ aggregates leading to the expression of inflammatory cytokines. The initial 
inflammatory response is beneficial and necessary to prevent the neurotoxicity caused by 
amyloid fragments and to limit the disease progress. Generated cytokines act directly on 
the neurons and stimulate the astrocytes, and chemokines can also recruit peripheral 
immune cells to injured regions of the brain. Both mechanisms amplify the pro-
inflammatory responses, which cause neurotoxic effects and contribute to neuronal 
death. In an advanced AD phase, due to the persistent activation of microglia, chronic 
neuroinflammation occurs. Chronic inflammation found in AD brains has been recognized 
as sign and a fundamental mechanism involved in pathological disease progression. Thus 
far, different inflammatory markers have been addressed in CSF and serum of AD 
patients, nonetheless conflicting results have been described. Since the identification of 
AD biomarkers will aid in the differential diagnosis of this disease from other dementia 
subtypes, the main aim of this project was to identify inflammatory biomarker candidates 
for AD and/or dementia. In particular, as CSF collection is an invasive procedure, 
investigation has been directed towards the search of noninvasive peripheral biomarkers. 
Therefore, the following specific aims were to: 
 
o Evaluate the profile of inflammatory proteins in plasma samples of patients with 
cognitive decline, including a group of possible AD patients; 
 
o Address the relation between the inflammatory biomarkers evaluated and the 
cognitive tests applied in our study population; 
 
o Establish correlations between the inflammatory biomarkers analysed; 
 
o Setup the experimental conditions to determine the effects of the most promising 
inflammatory candidates on APP processing. 
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III. Methods 
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3.1. Study subjects 
For this study, plasma samples from control individuals and patients with cognitive 
decline were analysed. Patients were subgrouped based on the individual cognitive 
evaluation as described below (Section 3.1.2). 
 
3.1.1. Sample collection 
Plasma samples were collected and processed within 1h after collection, according 
to standard procedures in an EDTA tube (K2 EDTA with gel, 5 mL), to prevent coagulation. 
Once arrived at the laboratory, samples were centrifuged at 1800 g, for 15 minutes at 
4oC. Supernatant was transferred for a new tube and ressuspended. Samples were 
aliquoted (each with 500 µL) and frozen at -80°C. 
 
3.1.2. Cognitive evaluation 
Plasma samples were obtained from the group of 46 individuals, selected from the 
CBC Cohort project based on the cognitive evaluation criteria. Cognitive evaluation of 
individuals was carried out at several Centers for Primary Health Care in the Aveiro 
region. The project was approved by the ethics committee of the Regional Health Center - 
Coimbra, protocol number 012 804 of April 4, 2012. 
The inclusion criteria for this study group were: age between 50-90 years, resident 
in the Aveiro region, with complaints that include objective memory impairment or other 
cognitive complains. The exclusion criteria were individuals undergoing chemotherapy or 
radiotherapy, psychiatric illness such as bipolar disorder, schizophrenia, and the use illicit 
drugs.  
The cognitive tests applied to the study group were the Clinical Dementia Rating 
scale (CDR) (Hughes et al. 1982), the Mini-Mental State Examination (MMSE) (Folstein et 
al. 1975) and the Geriatric Depression Scale (GDS) (Mitchell et al. 2010). 
According to the CDR scale: 0 indicates normal function; 0.5 indicates a transition 
level (termed very mild dementia); 1.0 indicates significant loss (almost always a clear 
correlation with dementia); 2.0 indicates loss of moderate cognitive function; 3.0 
indicates severe loss. For this study cognitive dysfunction was considered when CDR ≥ 0.5.  
The MMSE test allows patient stratification according to the education level: 
cutoff of 22 for 0-2 years schoolarship; 24 for 3-6 years; and 27 for more than 7 years 
(Morgada et al. 2009). Additionally, clinical routine questions were included to address 
other possible neurological pathologies.  
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Depressed individuals were excluded from the group using the GDS scale. The GDS 
test (Mitchell et al. 2010) consists of 15 questions, to survey for symptoms suggestive of 
depression, in which individuals with 0-5 positive questions were considered normal. 
According to the cognitive evaluation, individuals were subdivided in 3 groups: a 
control group (negative for CDR and MMSE tests); a group with cognitive alteration but 
MMSE negative (CDR positive and MMSE negative); and a possible AD group (positive for 
both CDR and MMSE scales), in which 5 of 12 patients are clinically diagnosed with AD. 
Table 3 presents the age variable and total number (n) of the study group individuals. 
 
 
 
 
Plasma Samples 
 
Subgroups/ 
Characteristics 
CDR- 
 MM- 
CDR+ 
 MM- 
CDR+  
MM+ 
Age (years) 
Mean 
Min-Max 
 
76 
65-82 
 
74 
70-84 
 
79 
72-88 
Gender 
Male      n 
Female  n 
N total 
 
8 
17 
25 
 
3 
6 
9 
 
1 
11 
12 
 
 
3.2. Flow cytometry analysis 
Flow cytometry is a fast, objective and quantitative method, useful for detection 
of cell surface markers, intracellular factors, cell-secreted factors, DNA content, among 
others. This process allows the measurement and counting of the physical and chemical 
characteristics of biological particles. 
In this study, inflammatory proteins in peripheral biological samples were 
analyzed by flow cytometry, using a cytometric bead array (CBA). CBA allows the specific 
detection of soluble proteins (in this case cytokines and chemokines) in complex 
biological fluids. CBA is a multiplexed bead-based immunoassay, in which beads are 
couple with high-affinity antibodies for the markers of interest, allowing to quantify 
multiple proteins simultaneously in the same sample.  
After bead incubation with the biological sample, phycoerythrin (PE)-conjugated 
antibodies were added, providing a fluorescent signal proportional to the amount of the 
bound analyte (Figure 8). Each bead population is classified with an alphanumeric 
Table 3 – Characteristics of age variables and n total from the study groups.  
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position indicating its position relatively to other beads in the CBA array, which allows the 
distinction of the fluorescent signal of each protein analyzed. It permits beads with 
different positions to be combined and used at the same time, creating a multiplex assay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The IL-1β, IL-6, IL-8, MCP-1 and RANTES were the inflammatory proteins analysed 
in this work according to the manufactures’ instructions (CBA Human Soluble Protein Flex 
Set System, from BD Biosciences). Depending on the number of tests in the experiment, a 
specific volume of each capture bead (1 µL/test) was mixed in 0,5 mL of Washer Buffer. 
The resulting solution was then centrifuged at 200 g for 5 minutes. Supernatant was 
removed and the mixed beads ressuspended in Capture Bead Diluent to a final 
concentration of 50 µL/test. Mixed beads solution was then added to samples. PE 
Detection Reagent was also dependent on the number of tests (1 µL/test) as well as the 
total volume of diluted PE Detection Reagent needed for the experiment, being that each 
test tube requires 50 µL of this diluted reagent. The PE Detection Reagent of each protein 
were mixed and diluted, before adding to samples, according to manufacturer’s 
instructions. For quantitative analysis of these proteins, a standard curve was prepared as 
mentioned in Table 4. 
Samples were analysed and acquired on Accuri C6 Flow Cytometer (BD 
Biosciences), using FCAP Array™ software to generate results in graphical and tabular 
format. 
 
 
 
 
 
 
Figure 8 – Principle of the CBA Soluble Protein Flex Set System. 
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3.2.1. Data analysis 
Statistical analyses were performed using the SPSS 21.0 software. The flowchart 
below represents the sequential steps for statistical analysis of the flow cytometry data. 
The Shapiro-Wilk test was used to examine normal distribution. Data analyses were 
carried out using non-parametric tests, since the normality test was not validated for our 
population. Comparisons between groups were performed applying the Kruskal-Wallis 
test. The graphs were presented in box plots format, enabling the observation of outliers 
in different groups of the study population, which were plotted as individual points. 
Additional statistical analysis was carried out using the Wilcoxon Signed Rank test for the 
21 paired age- and sex-matched pairs. Furthermore, Spearman's Rank Order was used for 
correlation analysis between the inflammatory proteins, as well as to verify the 
correlation of the inflammatory proteins with CDR scores. To test if the results are or not 
significant, the null hypothesis (H0) was imposed. With a confidence interval (CI) of 95%, 
p<0.05 was considered statistically significant, rejecting H0.  
 
 
 
 
 
 
Standard dilution Concentration 
(pg/mL) 
No standard dilution  
(Assay Diluent only) 
0 
 
1:256 10 
1:128 20 
1:62 40 
1:32 80 
1:16 156 
1:8 312,5 
1:4 625 
1:2 1250 
Top Standard 2500 
Table 4 – CBA standards preparation.  List of standard dilution and respective concentration 
(pg/mL). 
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Figure 9 – Statistical analysis workflow for the study group. 
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3.3. Cell culture experiments 
A set of experiments were carried out in SH-SY5Y cells. These are human cells 
derived from the original cell line SK-N-SH, isolated from a bone marrow biopsy of a 
neuroblastoma patient. SH-SY5Y cells were maintained in Minimal Essential Medium 
(MEM):F12 (1:1) supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine and 
1% antibiotic/antimycotic mix. Cells were maintained in an atmosphere of 5% CO2 at 37°C 
and split when 80-90% confluent. Cells were plated at a density of 5x105 cells per well 
(12-well plates) or 1,3x105 cells/cm2. 
 
3.3.1. IL-8 experimental procedures 
Cells were incubated with crescent concentrations of IL-8 (BD Biosciences) for 
different periods of time, 6 and 24 hours. Lyophilized IL-8 was reconstituted in distilled 
water (20 µg stock), aliquoted and stored. For experimental purposes IL-8 stock solution 
was subsequently diluted in serum free culture medium at the final concentrations of 10, 
50 and 100 µM and then added to cells.  
 
3.3.2. Sample collection and immunodetection 
After the appropriate treatments, cells lysates were collected in RIPA buffer. 
Samples were stored at -20oC. Protein determination content was performed using BCA 
assay (see below) and normalized protein samples were electrophoretically separated by 
7.5% SDS-PAGE gels (Section 3.3.2.2.). Separated proteins were transferred onto a 
nitrocellulose membrane (Section 3.3.2.3.1.) followed by immunoblotting for the specific 
protein (Section 3.3.2.1.). Detection was carried out using a chemiluminescent method 
(Section 3.3.2.3.2.) and the resulting bands were quantified by densitometry (Section 
3.3.3.). 
 
3.3.2.1. Protein concentration determination 
The bicinchonic acid (BCA) protein assay (Pierce) was used for the colorimetric 
detection and quantification of total protein concentration. This test is based on the 
capability of proteins to reduce Cu2+ to Cu+ in an alkaline environment (the biuret 
reaction). BCA produces a purple color in the presence of the reduced Cu+ ion that results 
from chelation of two molecules of BCA with one cuprous ion. These soluble complexes 
exhibit a strong absorbance that can be read at 562 nm.  
The quantitative analyses were carried out using 5 µL of the collected cell lysates. 
To determine the total protein content in each sample a standard curve was prepared as 
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described in Table 5. Samples and standards were incubated with 200 µL of working 
reagent, which is prepared with 50 parts of Reagent A to 1 part of Reagent B. All samples 
were incubated at 37°C during 30 minutes, cooled to room temperature and immediately 
measured at 562 nm. 
 
  
 
Standard BSA (µL) SDS 1% (µL) Final Protein Mass 
(µg) 
P0 - 25 0 
P1 1 24 2 
P2 2 23 4 
P3 5 20 10 
P4 10 15 20 
P5 20 5 40 
 
 
3.3.2.2. SDS-polyacrylamide gel electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is an 
analytical method used to separate components of a protein mixture based on their 
molecular weight and negative charge. The principle of SDS-PAGE relies on the capacity 
for proteins to migrate through gel pores when submitted to an electrical field. The gel 
percentage and size depend on the molecular weight of the proteins to be separated. As 
proteins have different electrical charges that affect their mobility, SDS is usually added to 
protein samples and buffers to confer a negative charge to all proteins, ensuring protein 
migrate toward the positively charged anode. SDS is also used in combination with a 
reducing agent (mercaptoethanol) and heated to dissociate proteins before they are 
loaded on the gel. SDS also breaks up aggregates and non-covalently bound multimers. 
Gels comprise 2 phases, the non-restrictive large pore called stacking gel and the 
resolving gel with an acrylamide concentration of 7,5%. The gel was prepared and 
allowed to polymerize at room temperature for 45 minutes. Subsequently, the stacking 
gel solution was prepared and loaded on the top of the resolving gel, and left to 
polymerize at room temperature for 30 minutes. 
The samples to be run on the gel were boiled in SDS gel loading buffer for 5 
minutes to ensure protein denaturation. Precision plus protein standards Dual Color 
(BioRad) was used as marker. Proteins were separated electrophoretically at 90 mA for 
approximately 3 hours in a Hoefer electrophoresis system. 
 
Table 5 – Standards used in BCA protein assay method. BSA, Bovine Serum Albumin solution (2mg/mL). 
 
Standard BSA (µL) SDS 1% (µL) 
P0 0 25 
P1   
P2   
P3   
P4   
P5   
 Table 5 – Standards used in BCA protein assay method. BSA, Bovine Serum Albumin solution (2mg/mL). 
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3.3.2.3. Western blotting analysis 
Western blotting is the technique used for detection of specific proteins in 
complex samples like cell lysates, cell culture supernatants or body fluids. In this 
technique, proteins separated by SDS-PAGE were transferred to a solid membrane by the 
application of an electrophoretic field. This is a fast and efficient procedure and preserves 
the high-resolution separation of proteins by SDS-PAGE. In the membrane, proteins are 
suitable to detection by total protein staining or labeling of the proteins of interest with 
specific antibodies. 
 
3.3.2.3.1. Transfer of Proteins from the membrane to a Solid Support 
 
Proteins were electrophoretic transferred to a nitrocellulose membrane. The gel 
was placed in contact with a nitrocellulose filter and then sandwiched between Whatman 
3 MM paper, two porous pad and two plastic supports. The nitrocellulose filter was 
placed toward the anode. An electric current of 200 mA was applied for at least 16 hours. 
After proteins transfer, the membrane was removed from the sandwich and allowed to 
dry at room temperature. 
 
 
3.3.2.3.2. Immunological Detection of the Immobilized Proteins – 
Chemiluminescent Protein Detection 
 
For APP detection the Rabbit polyclonal antibody anti-APP (APP C-Terminal) was 
used to detect full-length APP.  The mouse monoclonal anti-APP (22C11, N-Terminal) was 
used to detect the APP N-terminal fragments (sAPP) in the conditioned medium. 
Membranes were initially soaped in 1x TBS for 5 minutes. Blocking of possible 
non-specific binding-sites of the primary antibody was performed using 5% (w/v) BSA in 
1x TBS-T solution. Subsequently, membranes were incubated with an unlabeled primary 
antibody direct against the target protein for 4 hours with agitation at room temperature 
plus overnight incubation at 4oC. After washing with 1x TBS-T (3 times, 10 min each) 
membranes were incubated with the secondary antibody (coupled with horseradish 
peroxidase) for 2 hours. Membranes were additionally washed 3 times with 1x TBS-T 
before protein detection.   
The detection method (Table 6) used was enhanced chemiluminescence (ECL) 
reagent. This method is based on the oxidation of the cyclic diacylhydrazide luminal that 
results in light emission. The membranes were incubated with the working mixture of the 
chemiluminescent detection reagent, for 1 minute at room temperature. The membranes 
were exposed to autoradiography films (Kodak) in an X-ray film cassette. Films were 
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exposed for different periods in order to optimize signal, developed and fixed with 
appropriate solutions (Kodak). 
 
 
 
 
3.3.2.4. Ponceau red staining of protein bands 
Ponceau Red staining was applied as a loading control. This type of staining has 
been described as a fast, inexpensive, and nontoxic method and its binding is fully 
reversible in a few minutes (Romero-Calvo et al. 2010). The nitrocellulose membrane was 
incubated in Ponceau S solution (Sigma Aldrich) for 5 minutes, followed by a brief rinse in 
deionized water (destain) so that the bands were made visible. The membrane was then 
scanned in a GS-800 calibrated imaging densitometer (Bio-rad). After that, the membrane 
was extensively washed with 1x TBS-T and deionized water to remove staining. 
 
3.3.3. Quantitative analysis 
Quantity One Densitometry software (Bio-Rad) was used to quantify band 
intensities of the immunoblots. 
Protein First Antibody Species 
Reactivity 
Secondary Antibody Detection 
Method 
 
APP C-
Terminal 
Rabbit anti-APP 
Dilution 1:1000 
(Invitrogen) 
Human, 
mouse, pig, 
rat 
Peroxidase labeled anti-
rabbit 
Dilution 1:5000 
(Amersham Pharmacia) 
 
ECL 
 
22C11 
 
Mouse anti-APP 
(N-Terminal) 
Dilution 1:250 
(Boehringer) 
 
Rat, human, 
monkey 
Peroxidase labeled anti-
mouse 
Dilution 1:5000 
(Amersham Pharmacia) 
 
Luminata™ 
Crescendo 
Table 6 – Antibodies and detection method used for protein immunodetection.  
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4.1. Inflammatory biomarker profile in plasma samples 
 
Neuroinflammatory process plays a key role in dementia and AD. As such many 
studies have addressed the potential of inflammatory biomarkers in AD diagnosis, 
however controversial findings have been reported. In an attempt to aid in the 
clarification of this issue, in this project we aimed to evaluate a panel of putative 
inflammatory biomarkers, in particular cytokines, in plasma samples, which is a biological 
fluid extensively used for the identifications of non-invasive peripheral biomarkers for AD. 
Samples were obtained from the CBC Cohort study and collected and selected as 
described in section 3.1 of methods. 
Different inflammatory proteins were evaluated, 2 interleukines (IL-1β, IL-6) and 3 
chemokines (IL-8, MCP-1, RANTES) in plasma samples by flow cytometry. These 
biomarkers were selected, based on the literature. Data were obtained for IL-6, IL-8, 
RANTES and MCP-1. Unexpectedly, IL-1β could not be detected in plasma samples, this 
could be related with sample storage at -80°C, potentially leading to IL-1β degradation. 
Therefore, for the purpose of this work, the biomarkers considered were IL-6, IL-8, MCP-1 
and RANTES. 
Plasma samples, included a total of 46 individuals that were subdivided into 3 
groups according to the cognitive evaluation results (Section 3.2.1, Methods). The control 
group (both CRD- and MM-), a group with cognitive alteration (CRD+ and MM-), that 
putatively include patients with mild cognitive (MCI) impairment, and a group of 
individuals (CDR+/MM+), which includes 5 patients clinically diagnosed for AD type 
dementia. To determine if the study subgroups population follow a normal distribution 
(Gauss Curve) and since each group is constituted by less than 30 individuals, Shapiro-
Wilk test was performed. Table 7 shows that subgroups do not follow a normal 
distribution thereby the subsequent statistical analyses were done using non-parametric 
tests (see flowchart, section 3.2.1 in methods). 
 
 
 
Test of Normality: Shapiro-Wilk 
 Statistic df p 
IL-6 0,23 39 0,00 
IL-8 0,85 39 0,00 
MCP-1 0,74 39 0,00 
RANTES 0,51 39 0,00 
 
 
Table 7 – Shapiro-Wilk test to check if the study population is normally 
distributed. 
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As mentioned, the detection of cytokines levels was performed by flow cytometry. 
Statistical analysis of the data obtained revealed that there was no difference in 
concentrations among the groups for IL-6, or neither for RANTES and MCP-1, as shown in 
Table 8.  However for the chemokine IL-8, a significant difference among groups was 
detected (p 0,05, Kruskal-Wallis test).  
 
 
 
 
Hypothesis Test Summary 
 
 
Null Hypothesis 
 
 
Test 
 
p 
 
Decision 
The distribution of IL-6 is the same 
across categories of Groups. 
 
 
 
 
Independent Samples 
 
Kruskal-Wallis 
 
0,08 
 
Retain the null 
hypothesis. 
 
The distribution of MCP-1 is the same 
across categories of Groups. 
 
 
0,89 
Retain the null 
hypothesis. 
The distribution of RANTES is the 
same across categories of Groups. 
 
 
0,93 
Retain the null 
hypothesis. 
The distribution of IL-8 is the same 
across categories of Groups. 
 
 
0,03 
Reject the null 
hypothesis. 
 
 
For IL-6 there were no statistically differences among the three study groups 
(p=0,08, Kruskal-Wallis test). Despite that box plot graphs (Figure 10) showed a slight 
increase of IL-6 levels from CDR+/MM- to CDR+/MM+ patients (possible AD type 
dementia) (0 vs 0,22 pg/mL, respectively). CDR+/MM- (Controls) did not differ from 
CDR+/MM- patients (both with 0 pg/mL).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8 - Hypothesis test summary for the cytokines tested. 
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Figure 10 – IL-6 concentrations for the three study groups. Flow cytometry analysis allowed 
the determination of the absolute value of IL-6 analyte in plasma samples. Control group 
(n=25), CDR+/MM- (n=9) and CDR+/MM+ (n=12). The middle line in the box represents the 
median. The Kruskal-Wallis test was applied, p=0,08 and Mean Rank: CDR-/MM-= 22,32; 
CDR+/MM-= 19,11; CDR+/MM+= 29,25. 
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Flow cytometry data analysis for MCP-1 and RANTES (Figure 11) did not show 
statistically significant differences between groups (p=0,89 and p=0,93, respectively, 
Kruskal-Wallis test). MCP-1 exhibited a median concentration level of 11,61 pg/mL in the 
CDR+/MM+ group, of 14,62 pg/ml in CDR+/MM- group and of 12,82 pg/ml in the CDR-
/MM- control individuals, showing a tendency to a slight increase from controls to 
putatively MCI patients (CDR+/MM-). RANTES showed a median concentration value of 
6279,42 pg/ml vs 5871,61 pg/ml (CDR+/MM+ vs CDR-/MM-). Both chemokines presented 
two common outliers, #33 and #35, in the CDR+/MM- and CDR+/MM+ groups 
respectively, which could contribute to a higher median value (middle line) of the total 
group. An outlier (#23) was present in the CDR-/MM- group for RANTES and also for IL-6.  
 
 
 
A. 
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Figure 11 – MCP-1 and RANTES concentrations for the three study groups. Flow 
cytometry analysis allowed the determination of the absolute value of (A) MCP-1 and (B) 
RANTES analytes in plasma samples. The Kruskal-Wallis test was applied for both 
chemokines. For MCP-1, some values could not be determined, and as such control group 
(n=22), CDR+/MM- (n=7) and CDR+/MM+ (n=10). p=0,89 and Mean Rank: CDR-/MM-= 
19,77; CDR+/MM-= 22,86; CDR+/MM+=18,5. For RANTES control group (n=25), CDR+/MM- 
(n=9) and CDR+/MM+ (n=12). p=0,93 an Mean Rank: CDR-/MM-= 24,16; CDR+/MM-= 
23,11; CDR+/MM+= 22,42. The middle line in the box represents the median. 
 
 
 
B. 
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Noticeably, statistical differences were detected in the case of IL-8 chemokine 
(Figure 12), for which decreased levels were observed in both patients groups when 
compared to controls subjects. While control individuals (CDR-/MM-) exhibited an IL-8 
concentration mean value of 1,43 pg/ml the possible AD group exhibited a mean value of 
0,75 pg/ml (p0,05, Kruskal Wallis test). The concentrations values among groups appear 
to be more consistent than for the other inflammatory markers tested, since only the 
CDR+/MM+ patients group exhibited one outlier (#44), also presented in IL-6, with higher 
IL-8 concentrations. This may also explain the slight increase in the median value of this 
group when compared to CDR+/MM- group (0,57 pg/ml). The outlier #33, was present in 
all the other inflammatory markers (Figure 10 and 11), except for IL-8.  
 
 
 
 
 
 
 
 
 
Figure 12 – IL-8 concentrations for the three study groups. Flow cytometry analysis allowed the 
determination of the absolute value of IL-6 analyte in plasma samples. Control group (n=25), CDR+/MM- 
(n=9) and CDR+/MM+ (n=12). The middle line in the box represents the median. The Kruskal-Wallis test 
was applied, p=0,03 and Mean Rank: CDR-/MM-= 28,32; CDR+/MM-= 17,33; CDR+/MM+= 18,08. 
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4.1.1. Paired analysis of the inflammatory biomarkers 
The IL-8, MCP-1, RANTES and IL-6 concentrations obtained for the plasma samples 
of patients with cognitive alterations (PCA), either CDR+/MM- or CDR+/MM+, were paired 
with age- and sex-matched CDR-/MM- individuals (C, Control individuals) (n=21 pairs), as 
displayed in Table 9. A Wilcoxon Signed Rank test was used for statistical analysis and, 
consistently with the data previously presented, statistically significant differences were 
detected for the IL-8 inflammatory protein (p=0,02). None of the other inflammatory 
proteins were statistically different among the PCA and C groups. 
 
 
 
 
 
 
 
 
 
 
C 
nr. 
PCA 
nr. 
C 
IL-8 
n=21 
pg/mL 
PCA 
IL-8 
n=21 
pg/mL 
C 
MCP-1 
n=18 
pg/mL 
PCA 
MCP-1 
n=17 
pg/mL 
C 
RANTES 
n=21 
pg/mL 
PCA 
RANTES 
n=21 
pg/mL 
C 
IL-6 
n=21 
pg/mL 
PCA 
IL-6 
n=21 
pg/mL 
1 22 0,22 0,42 5,19 14,33 3486,16 10826,79 0,00 0,00 
2 23 0,46 1,22 14,65 14,92 16140,80 1510,29 0,00 0,00 
3 24 1,42 0,00 8,24 7,56 11079,45 11668,23 0,14 0,00 
4 25 1,44 1,03 22,41 N. D. 41258,67 11432,98 0,00 0,00 
5 26 1,56 0,00 14,15 8,00 2779,10 7936,35 0,00 0,00 
6 27 3,53 0,99 12,85 9,50 9227,55 22442,50 0,56 0,00 
7 28 1,99 0,36 32,94 13,35 9351,03 3013,26 0,13 0,45 
8 29 2,22 0,63 14,49 N. D. 15781,65 7352,59 0,00 0,00 
9 30 2,64 1,01 23,59 66,11 2854,28 45764,34 0,32 0,62 
10 31 1,62 0,03 N. D. 8,30 34064,93 7111,73 3,72 0,59 
11 32 1,39 0,11 N. D. 5,95 2166,80 1569,95 0,00 0,00 
12 33 1,58 5,24 5,95 10,39 3088,88 3574,52 0,00 45,55 
13 34 1,73 0,00 5,14 8,24 2327,29 4458,37 0,00 11,81 
14 35 0,36 0,71 10,25 N. D. 12792,91 6779,46 0,00 0,00 
15 36 0,49 0,87 10,96 24,44 27081,41 113577,00 0,00 2,01 
16 37 1,44 0,91 13,50 13,50 5756,63 1269,16 0,00 0,00 
17 38 1,42 0,44 6,31 14,84 3361,64 11696,21 0,00 1,37 
18 39 0,00 1,10 N. D. N. D. 13960,64 13312,11 0,00 0,00 
19 40 0,52 0,40 12,82 21,52 4128,39 1913,89 0,00 0,00 
20 41 2,09 1,41 28,46 12,18 114313,90 3296,53 0,67 0,00 
21 42 1,91 1,06 35,02 12,82 16745,53 4631,49 0,00 0,00 
Wilc. p IL-8 0,02 MCP-1 0,69 RANTES 0,43 IL-6 0,33 
Table 9 – Paired analysis of the cytokines in plasma samples. Concentrations of IL-8, MCP-1, RANTES and IL-6 in the 
plasma of patients with cognitive alterations (PCA) that include the CDR+/MM- and CDR+/MM+ patients and age- and 
sex- matched CDR-/MM- (C) (n=21 pairs).  
p values are displayed as well (Wilcoxon Signed Rank Test).  
N. D. – Not Determined 
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4.2. IL-8 correlations with CDR stages 
 
Patients with cognitive decline were evaluated by the CDR and the MMSE tests. 
Correlation analysis of both tests with our inflammatory biomarker candidates revealed 
that only IL-8 concentrations correlated with CDR (Table 10, Spearman´s Correlation). A 
statistical significant (p<0,01) negative correlation was detected for CDR scores:IL-8 
concentrations (r=-0,38, p=0,009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CDR is a five-point scale in which CDR-0 indicates no cognitive impairment, and the 
remaining four points refers to various stages of dementia (very mild or suspected 
dementia, mild, moderate and severe). 
Kruskall-Wallis test was used for statistical analysis of IL-8 concentrations in the 
CDR groups independently. No significant differences were detected for IL-8 and MM. IL-8 
was decreased in the 4 stage groups of CDR (p0,05), as seen in Figure 13. A higher 
decrease in IL-8 concentrations could be observed for the mild dementia group, which 
could be related to a decrease number of subjects at this stage. 
 
 
 
 
 
 
 
 
Correlations 
 IL-8 CDR 
Stages 
 
 
 
Spearman’s 
Correlation 
 
 
IL-8 
Correlation 
Coefficient 
1 -0,38** 
P - 0,009 
N 46 46 
 
CDR 
Stages 
Correlation 
Coefficient 
-0,38** 1 
P 0,009 - 
N 46 46 
Table 10 – Correlation between IL-8 and CDR scores by Spearman’s Correlation.  
** Correlation is significant at the 0,01 level (p). 
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Figure 13 – IL-8 and CDR stages correlation. Box plot graph presenting the IL-8 levels in each score group 
of the CDR diagnosis exam by Kruskall-Wallis test showing statistically significant differences (p=0,009). 
Normal (n=25); Very Mild or Suspected (n=8); Mild (n=3); Moderate (n=6) and Severe (n=4). 
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4.3. Inflammatory proteins correlations 
In order to evaluate if the cytokines correlate between them, the Spearman’s 
Correlation was used. Data are presented in Table 11. Considering all subjects studied, a 
positive correlation, that was statistically significant (p<0,05), between the concentrations 
of IL-8 and MCP-1 (r= 0,32, p=0,03) and between IL-6 and MCP-1 (r= 0,31, p=0,04) could 
be observed. No significant correlations were identified for the other inflammatory 
protein concentrations (IL-8:IL-6 r=0,22, p=0,15; IL-8:RANTES r=0,07, p=0.64; MCP-
1:RANTES r=0,22, p=0,15; RANTES:IL-6 r=0,26, P=0,08).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correlations 
 IL-8 MCP-1 RANTES IL-6 
 
 
 
 
 
 
Spearman’s 
Correlation 
 
IL-8 
Correlation 
Coefficient 
1 0,32* 0,07 0,22 
P - 0,03 0,64 0,15 
N 46 46 46 46 
 
MCP-1 
Correlation 
Coefficient 
0,32* 1 0,22 0,31* 
P 0,03 - 0,15 0,04 
N 46 46 46 46 
 
RANTES 
Correlation 
Coefficient 
0,07 0,22 1 0,26 
P 0,64 0,149 - 0,08 
N 46 46 46 46 
 
IL-6 
Correlation 
Coefficient 
0,22 0,31* 0,26 1 
P 0,15 0,04 0,08 - 
N 46 46 46 46 
Table 11 – Correlations of the inflammatory proteins. Spearman's Correlation was used for correlation 
analysis. * Correlation is significant at the 0,05 level (p). 
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4.4. IL-8 effects on APP processing 
IL-8 appears to be the most promising candidate inflammatory biomarker, as such 
its effects on APP were addressed. Few studies focused on the effects of cytokines on APP 
processing and Aβ production, and to our knowledge, little is known about IL-8 effects on 
APP processing. Therefore, preliminary experiments were carried to address this issue. 
Upon IL-8 incubation for 6h no differences could be detected for APP and sAPP secretion. 
Despite that at 24h, APP levels showed a tendency to increase in a dose-dependent 
manner, as shown in Figure 14. This was not accompanied by an increase on sAPP 
secretion (22C11, N-terminal APP antibody). In particular, for the longer incubation period 
and at the highest concentration (100 pg/mL), APP levels increased, by 0,7 fold when 
compared to non-IL-8 treated cells, as detected by the APP C-terminal antibody. Data 
suggest that IL-8 may impact on APP metabolism, but additional experiments need to be 
carried out. 
 
 
 
Figure 14 – IL-8 effects on APP processing. Upon IL-8 treatment for 6h and 24h, SH-SY5Y cells lysates 
and conditioned media were collected. Conditioned media were probed with the APP N-terminal 
22C11 antibody and cell lysates with the APP C-Terminal antibody. Quantification of APP levels by 
densitometric scanning was normalized to protein levels determined by Ponceau S staining. 
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V.  Discussion 
  
Inflammatory Biomarkers in Alzheimer’s Disease                                                                     Cátia Barra 
 
58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Inflammatory Biomarkers in Alzheimer’s Disease                                                                     Cátia Barra 
 
59 
 
 
Cognitive decline is a common feature of several neuropathologies, which 
complicates differential diagnosis of dementia subtypes. AD is one of the most common 
forms of dementia characterized by progressive cognitive decline, whose diagnosis 
requires a set of clinical and neurological examinations and evaluations to exclude other 
forms of dementia. Recently, a promising and accurate tool has emerged that test for a 
panel of CSF biomarkers, which together with the clinical examination, allows, distinction 
among neurodegenerative diseases, such as AD. However, CSF collection is an invasive 
procedure that requires a lumbar puncture, involves clinical doctors support and may 
have additional complications.  Hence, many studies have addressed the potential of 
peripheral biomarkers in the diagnosis of AD, and other neuropathologies. Among the 
factors that may contribute to AD progression is neuroinflammation. Studies have 
focused on the potential of inflammatory biomarkers in AD diagnosis, however many of 
these data are still controversial. In this work we aimed to evaluate a panel of putative 
inflammatory biomarker candidates in plasma samples, of patients with cognitive decline, 
and with possible AD type dementia. 
We evaluated different cytokines, including IL-6 and three chemokines (IL-8, MCP-
1 and RANTES) in plasma samples of patients with cognitive alterations, which were 
identified by CDR and MM diagnostic tests. CDR is a numeric scale used to quantify the 
dementia severity symptoms that range from very mild (or suspected) to severe dementia 
stages. MM test also detects dementia, and several studies demonstrated that it is 
possible to distinguish some types of dementia with this diagnostic exam. A recent study 
showed lower points at baseline MM scores for AD patients comparatively to patients 
suffering from subtypes of frontotemporal lobar degeneration (FTLD) (Tan et al. 2013). 
The same work also showed that MM scores declined significantly faster in patients with 
AD than in the 2 FTLD subtypes analysed. Another study suggested that MM may be 
helpful in the differentiation of DLB and AD (Ala et al. 2002). In this sense, MM is a useful 
tool to detect dementia and cognitive alterations and putatively to aid in the 
identification of AD type dementia. 
The panel of inflammatory proteins was evaluated in normal subjects, without 
cognitive dysfunction (the group designated as CDR-/MM-), in individuals with cognitive 
impairment that were negative for MM (designated as CDR+/MM-) and individuals with 
cognitive impairment that were positive for MMSE test (designated CDR+/MM+). The 
latest group included 5 patients that were already clinically diagnosed as AD patients. 
Most patients with MCI, from which 2 in 10 can progress to AD (Risacher et al. 2009; 
Kester et al. 2011; http://www.nia.nih.gov/alzheimers/publication/part-2-what-happens-
brain-ad/changing-brain-ad), may present a normal MM test. Therefore our CDR+/MM- 
group can potentially include MCI patients.  
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In particular, IL-6 is a cytokine produced by neurons, microglia, astrocytes and 
endothelial cells, and it is up-regulated in CNS diseases where neuroinflammation has a 
key role (Erta et al. 2012). This pro-inflammatory protein is increased around SP in AD 
brains and IL-6 was shown to play a role in AD by increasing Aβ phagocytosis by microglia 
(Chakrabarty et al. 2010), supporting the notion that IL-6 could impact on Aβ clearance. 
IL-6 were reported to be increased in both CSF and plasma samples of AD patients (Hüll et 
al. 1996; Hampel et al. 2005; Licastro et al. 2000). Cojocaru et al. (2011) also reported an 
increase of IL-6 levels in serum of clinically diagnosed AD patients comparatively to 
controls. Studies suggested that elevated plasma levels of IL-6 increase the risk of 
developing dementia (Engelhart et al. 2004). In our work, for the majority of the samples, 
IL-6 levels were very low (around zero), although a tendency for an increase was observed 
for the CDR+/MM+ patients (0,22 pg/mL). Therefore, although our results were not 
statistically significant the tendency observed is in agreement with literature data. 
Nonetheless, it would be important to increase the number of samples in an attempt to 
better define the profile of this cytokine in AD patients. Moreover, and this is true for all 
cases, we cannot exclude that the methodology of sample collection and processing, the 
cognitive selection criteria used and that the interindividual variations may underlie and 
explain the differences between studies. 
Among the chemokines analysed is RANTES, which is produced by astrocytes. 
RANTES, but also MCP-1 expression has been associated with a wide range of 
inflammatory disorders and some neurological diseases, including AD. According to Larlori 
et al. (2005) and Reale at al. (2012), higher levels of RANTES were evident in the plasma of 
AD compared to healthy subjects. However, like for many other cytokines, contradictory 
studies report that RANTES expression levels were lower in AD patients blood samples 
than in controls subjects (Kester et al. 2012). In our study group, no significant differences 
could be detected for the possible AD group (CDR+/MM+ group) when compared to the 
control individuals (CDR-/MM- group).  
Other of the chemokines tested is MCP-1 that is produced by microglia and is able 
to stimulate astrocytes, participating in Aβ deposits elimination. Consistent data have 
been reported for this chemokine in AD. A significantly increase of MCP-1 levels in plasma 
and serum of MCI and mild AD patients but not in severe AD cases, when compared to 
controls have been reported (Galimberti, Fenoglio, et al. 2006; Kim et al. 2011), 
suggesting that MCP-1 plasma levels could be a useful biomarker to monitor the 
inflammatory process in AD. Similarly, according to Reale et al. (2012), lower plasma 
MCP-1 levels were detected in AD patients when compared with control individuals 
(Reale et al. 2012). However, in the present work, despite the slight decrease in the 
possible AD (CDR+/MM+) group, and the slight increase in the group that putatively 
include MCI patients (CDR+/MM-), comparatively to control individuals (CDR-/MM-), no 
statistically significant differences could be observed among the 3 groups.  
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As the case for IL-6, increasing the number of subjects could clarify the cognitive 
decline associated profile of this chemokine.  
For all the above mentioned proteins, some outliers could be detected. These 
divergent values correspond to patients that presented levels higher or lower protein 
than median (for this case 3 standards deviations), which are automatically calculated and 
identified by the statistical program. Nonetheless, these values were not excluded from 
the median values calculated for each group. We analyzed each case individually. The 
outlier #23 is a control (CDR-/MM-) subject, with no cognitive dysfunction or other 
pathology reported; however, it was found altered for IL-6 and RANTES. This apparently 
healthy individual may have an unknown dysfunction or take some medication that leads 
to the changes observed in these cytokine levels. Another outlier that appears in these 
inflammatory proteins is #33, classified as a CDR+/MM- patient. This individual has 
several diseases including psychiatric disturbances. Neurological alterations, others than 
cognitive ones, as depression, can change the inflammatory components levels (Raison 
and Miller 2011; Najjar et al. 2013). The #35 outlier belongs to the CDR+/MM+ group and 
showed higher concentration levels for MCP-1 and RANTES chemokines. Similarly to #33, 
this outlier also presents psychiatric disorders among other diseases (arterial 
hypertension, dyslipidemia, gastric disease, osteoarticular disease), which can affect 
chemokines concentrations. Of note, our study group excluded subjects positive for the 
GDS scale, however, we did not exclude patients that were undertaking medication for 
depression or other psychiatric disorders, and that can now be negative for GDS scale.  
Interestingly, significant differences arise for the IL-8 chemokine, which has been 
shown to have a protective role against Aβ-induced neurotoxicity (Ashutosh et al. 2011). 
However, many reports on IL-8 chemokine levels in MCI or AD are controversial. Despite 
that, previous studies mentioned that the circulating plasma IL-8 levels, were higher in 
controls than in MCI and AD patients (Kim et al. 2011). Our results were in agreement 
these findings showing a decrease of IL-8 concentration between both patients groups 
(CDR+/MM- and CDR+/MM+) and the control group (CDR-/MM-), statistically significant 
differences (p<0,05) according to Kruskal-wallis test. Of note, despite the presence of 
some common outliers for the other inflammatory biomarkers tested, only one outlier 
subject (#44) could be detected for IL-8. This suggests that this chemokine could be more 
specific for dementia than the other inflammatory proteins since it was not so affected by 
other pathologic conditions.   
Additionally, when control subjects (CDR-/MM-) were randomly sex- and age- 
matched with cognitive decline patients, significant differences were also detected for IL-
8, independently of the patient cognitive decline stage (p=0,02, Wilcoxon test). Taken 
together data suggest that IL-8 could be a putative biomarker candidate for cognitive 
decline, decreasing not only in CDR+/MM+ group (possible AD type dementia) but also in 
CDR+/MM-group (that may include MCI individuals and represent initial stages of 
dementia). 
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A relation between IL-8 and the CDR scores was also observed. IL-8 concentrations 
significantly decrease with the different stages of cognitive decline when compared to 
normal individuals. In our study group, these IL-8 concentrations did not change 
consistently along dementia progression scores. However, once again, we should take in 
consideration the number of subjects in each scored group. Hence, it would be relevant 
to repeat this study with an increased number of subjects.   
Additionally, correlation analysis by Spearman’s test showed a significant 
correlation (p<0,05) between the concentrations of IL-6 and MCP-1 (r=0,31, p=0,04) and 
the concentrations of IL-8 and MCP-1 (r=0,32, p=0,03). Although not directly for AD, 
several data supports the interplay between these proteins and the correlations observed 
among them. Previous studies showed correlations between the MCP-1 mRNA levels and 
other cytokines mRNA levels, including IL-6, in rats autoimmune myocarditis (Kobayashi 
et al. 2002). Further, it was also reported that IL-6 stimulation induces higher expression 
of MCP-1 mRNA in a human myeloma cell line (Arendt et al. 2002) and that MCP-1 can 
stimulate markers of inflammatory activation such as IL-6 secretion (Viedt et al. 2002). 
MCP-1 and IL-8, both chemokines type inflammatory proteins, have common functions, 
e.g. in the neuroinflammation process (Gerszten et al. 1999), what may somehow support 
these correlations, as they can both be stimulated during that process. Moreover, it was 
also showed that these chemokines positively correlated and can serve as good indicators 
of local inflammation in pathologies such as rheumatoid arthritis (Slavic, Stankovic, and 
Kamenov 2005) and also in acute inflammation induced by prolonged exercise (Skenderi 
et al. 2010). Both MCP-1 and IL-8 levels correlated positively with age, and significantly 
increased in CSF of MCI and AD patients (Galimberti et al. 2006). Presently, it is difficult to 
interpret the significance of these correlations and additional studies in larger samples 
are needed to understand the importance of those associations in cognitive decline and 
AD pathology. 
As IL-8 appears to be the most promising candidate, experiments were also carried 
out to evaluate IL-8 effects on APP processing. Preliminary results showed that upon cell 
incubation with IL-8, there was a slight increase in the intracellular APP levels (APP not 
cleaved as detected by the APP C-terminal antibody), at the highest concentration and for 
the longer incubation period. Additional experiments should be directed for longer IL-8 
exposure periods and also for the evaluation of other fragments resulting from APP 
cleavage, as sAPPα/β and Aβ itself. The study of IL-8 effects on APP will help in the 
understanding of the function and involvement of this chemokine in dementia, in 
particular in AD neuroinflammation process and disease progression.  
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Conclusion & Future Perspectives 
In sum, cytokines and chemokines are important in triggering the immune 
response in CNS, being responsible for microglia and astrocytes activation and for 
recruitment of peripheral immune cells, respectively, to the site of Aβ deposition defining 
the extension of local inflammation. Hence, the release of these inflammatory agents may 
constitute potential biomarker candidates for AD diagnosis. The data herein presented 
suggests that IL-8 is the most promising peripheral inflammatory biomarker, useful for 
cognitive decline and AD detection. However, further studies will be needed to validate 
the results, particularly by increasing the number of subjects in the study group and also 
to include individuals with other neuropathological diseases, to address if IL-8 can be 
specific or not for dementia and/or AD. Of note, as AD is a multifactorial disorder it is 
expected that a panel of biomarkers, rather than a single biomarker, would be necessary 
to aid in a more specific and reliable disease diagnosis. 
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In this section are indicated the equipment and composition of solutions used for 
the different techniques applied. 
 
4.1. Flow Cytometry 
Equipment: 
 Accuri C6 Flow Cytometer (BD Biosciences) 
 
Reagents/Solutions: 
 CBA kit (BD Biosciences) 
 
4.2. Cell culture 
Equipment: 
 Hera cell CO2 incubator (Heraeus) 
 Safety cabinet Hera safe (Heraeus) 
 Inverted optical microscope (LEICA) 
 Hemacytometer (Sigma) 
 Sonicator (U200S IKA) 
 Bath SBB6 (Grant) 
 
Reagents/Solutions: 
 Complete medium 10% FBS MEM:F12 (1:1) 
- MEM (Gibco, Invitrogen)      4,805 g 
- F12 (Gibco, Invitrogen)      5,315 g 
- NaHCO3 (Sigma)       1,5 g 
- Sodium Pyruvate (Sigma)      0,055 g 
- 1% Antibiotic/Antimycotic (AA) mix (Gibco, Invitrogen)  10 mL 
- 10% FBS (Gibco, Invitrogen)      100 mL 
- L-Glutamine (200mM stock solution)    2,5 mL 
 
Dissolve in dH2O and adjust to pH 7,4 and to a final volume of 1000 mL in dH2O. 
Sterilize by filtering through a 0,2 µm filter and store at 4oC. 
 
 
 
  
Inflammatory Biomarkers in Alzheimer’s Disease                                                                     Cátia Barra 
 
76 
 
 
 PBS (1x) 
For a final volume of 500 mL, dissolve one pack of BupH Modified Dulbecco’s 
Phosphatase Buffered Saline Pack (Pierce) in deionized H2O. Final composition: 
- 8 mM Sodium Phosphatase 
- 2 mM Potassium Phosphatase 
- 140 mM Sodium Chloride 
- 10 mM Potassium Chloride 
Sterilize by filtering through a 0,2 µm filter and store at 4oC 
 
 
 RIPA buffer (Sigma-Aldrich) 
To 6,5 mL of RIPA buffer add: 
- 40,3 µL NaF 
- 65 µL NaO 
- 65 µL Protease inhibitor cocktail 
 
 
4.3. Protein content determination 
Equipment: 
 Infinite M200 (Tecan) and I-controlTM software 
 
Reagents/Solutions: 
 BCA assay kit (Pierce, Rockford, IL) 
 Bovine serum albumin (BSA) (Pierce) 
 Working reagent (50 Reagent A : 1 Reagent B) 
- Reagent A: sodium carbonate, sodium bicarbonate, BCA and sodium tartrate in 
0,2 N sodium hydroxide. 
- Reagent B: 4% cupric sulfate. 
 
 
4.4. SDS-PAGE 
Equipment: 
 Electrophoresis system (Hoefer SE600 vertical unit) 
 Electrophoresis power supply EPS 1000 (Amersham Pharmacia Biotec) 
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Reagents/Solutions: 
 Acrylamide stock mixture (30% acrylamide, 0,8% Bisacrylamide) 
To a 70 mL of deionized H2O add: 
- 29,2 g Acrylamide 
- 0,8 g Bisacrylamide 
Mix until the solute has dissolved. Adjust the volume to 100 mL with deionized 
water. Filter through a 0,2 µm filter and store at 4oC. 
 
 Stacking gel and resolving gel 
 
 Stacking gel Resolving gel 
 3,5% 7,5% 
H2O 13,2 mL 29,63 mL 
Acrylamide stock mixture 2,4 mL 15 mL 
UGB (5x) 4,0 mL -- 
LGB (4x) -- 15 mL 
10% APS 200 µL 300 µL 
10% SDS 200 µL -- 
TEMED 20 µL 30 µL 
 
 
 UGB (Upper gel buffer) (5x) 
To 900 mL of deionized H2O add: 
- 75,69 g Tris 
Mix until the solute has dissolved. Adjust the pH to 6,8 and adjust the volume to 1 
L with deionized H2O. 
 
 
 LGB (Lower gel buffer) (4x) 
To 900 mL of deionized H2O add: 
- 181,65 g Tris 
- 4 g SDS 
Mix until the solutes have dissolved. Adjust the pH to 6,8 and adjust the volume to 
1 L with deionized H2O. 
 
 
 APS (Ammonium Persulfate) 10% 
In 10 mL of deionized H2O dissolve 1 g of APS. Note: prepare fresh before use. 
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 SDS (Sodium dodecilsulfate) 10 % 
In 10 mL of deionized H2O dissolve 1 g of SDS. 
 
 
 Loading gel buffer (4x) 
- 2,5 mL (250 mM) Tris solution (pH 6,8) 1 mM 
- 0,8 g (8%) SDS 
- 4 mL (40%) Glicerol 
- 2 mL (2%) Beta-Mercaptoetanol 
- 1 mg (0,01%) Bromofenol blue 
Adjust the volume to 10 mL with deionized H2O. Store in darkness at room 
temperature. 
 
 
 Tris 1 M (pH 6,8) solution 
To 150 mL of deionized H2O add 30,3 g Tris base. Adjust the pH to 6,8 and adjust 
the final volume to 250 mL. 
 
 
 10x Running buffer 
- 30,3 g (250 mM) Tris 
- 144,2 g (2,5 mM) Glycine 
- 10 g (1%) SDS 
Dissolve in deionized H2O, adjust the pH to 8,3 and adjust the volume to 1 L. 
 
 
4.5. Western-Blotting 
Equipment: 
 Transphor Electrophoresis unit (Hofer TE 42) 
 Electrophoresis power supply EPS 1000 (Amersham Pharmacia Biotec) 
 
Reagents/Solutions: 
 1x Transfer buffer 
- 3,03 g (25 mM) Tris 
- 14,41 g (192 mM) Glycine 
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Mix until the solutes have dissolved. Adjust pH to 8,3 with HCl and adjust the 
volume to 800 mL with deionized H2O. Just prior to use add 200 mL of methanol 
(20%). 
 
 
4.6. Immunoblotting 
 
 10x TBS (Tris buffered saline) 
- 12,11 g (10 mM) Tris 
- 87,66 g (150 mM) NaCl 
Adjust the pH to 8,0 with HCl and adjust the volume to 1 L with deionized H2O. 
 
 
 10x TBS-T (TBS + Tween) 
- 12,11 g (10 mM) Tris 
- 87,66 g (150 mM) NaCl 
- 5 mL (0,05%) Tween 20 
Adjust the pH to 8,0 with HCl and adjust the volume to 1 L with deionized H2O. 
 
 
 Ponceau S solution 
Dissolve 0,1 g of Ponceau S (Sigma) in 100ml of 5% acetic acid solution (5 mL of acetic 
acid dissolved in 95 mL of deionized H2O).  
 
 
 Blocking solution 
5% of BSA (Bovine serum albumin, NZytech) in 1x TBS-T. 
 
 
 ECL Solutions 
- Luminata Crescendo (Millipore) 
- Home-made ECL: 
o Solution A – ECL Luminol Solution (Stock Solution) 
-      20 mM Luminol (in DMSO)* 1.25 mL (100 $M) 
-      100 mM 4-iodophenol (in DMSO)* 5 mL (2mM) 
-      0.1 M Tris (pH 9.35) 125 mL (50 mM) 
Adjust volume to 250 mL with dH2O.   * Protect from the light. 
o Solution B – Hydrogen Peroxide 
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 Developer and fixer solution (Sigma) 
 
 Membrane stripping solution 
- 3,76 g (62,5 mM) Tris-HCl (pH 6,7) 
- 10 g (2%) SDS 
- 3,5 mL (100 mM) Beta-mercaptoetanol) 
Dissolve Tris and SDS in deionized H2O and adjust with to pH 6,7. Add the 
mercaptoetanol and adjust volume to 500 mL. 
 
 
4.7. Quantitative analysis 
Equipment: 
 GS-710 calibrated imaging densitometer (Bio-Rad). 
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